WO2021222315A2 - Variant nucleic acid libraries for coronavirus - Google Patents
Variant nucleic acid libraries for coronavirus Download PDFInfo
- Publication number
- WO2021222315A2 WO2021222315A2 PCT/US2021/029485 US2021029485W WO2021222315A2 WO 2021222315 A2 WO2021222315 A2 WO 2021222315A2 US 2021029485 W US2021029485 W US 2021029485W WO 2021222315 A2 WO2021222315 A2 WO 2021222315A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- amino acid
- sequence
- set forth
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 185
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 167
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 167
- 241000711573 Coronaviridae Species 0.000 title description 27
- 238000000034 method Methods 0.000 claims abstract description 165
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims abstract description 143
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims abstract description 143
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 169
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 169
- 108091033319 polynucleotide Proteins 0.000 claims description 133
- 239000002157 polynucleotide Substances 0.000 claims description 133
- 102000040430 polynucleotide Human genes 0.000 claims description 133
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 97
- 239000012634 fragment Substances 0.000 claims description 50
- 239000000427 antigen Substances 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 241000282414 Homo sapiens Species 0.000 claims description 26
- 210000004602 germ cell Anatomy 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 20
- 238000003556 assay Methods 0.000 claims description 16
- 108020003175 receptors Proteins 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 15
- 208000025721 COVID-19 Diseases 0.000 claims description 12
- 101710114810 Glycoprotein Proteins 0.000 claims description 9
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 9
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 9
- 101710167605 Spike glycoprotein Proteins 0.000 claims description 9
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 65
- 108090000623 proteins and genes Proteins 0.000 abstract description 53
- 102000004169 proteins and genes Human genes 0.000 abstract description 38
- 150000001413 amino acids Chemical group 0.000 description 112
- 239000000758 substrate Substances 0.000 description 82
- 230000015572 biosynthetic process Effects 0.000 description 78
- 238000003786 synthesis reaction Methods 0.000 description 78
- 108020004705 Codon Proteins 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 48
- 241000700605 Viruses Species 0.000 description 45
- 230000035772 mutation Effects 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 37
- 238000005457 optimization Methods 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 210000004072 lung Anatomy 0.000 description 28
- 201000010099 disease Diseases 0.000 description 26
- 238000012163 sequencing technique Methods 0.000 description 26
- 241000699800 Cricetinae Species 0.000 description 25
- -1 antibodies Proteins 0.000 description 24
- 238000006386 neutralization reaction Methods 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- 108060003951 Immunoglobulin Proteins 0.000 description 20
- 102000018358 immunoglobulin Human genes 0.000 description 20
- 238000004091 panning Methods 0.000 description 20
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 19
- 229960004397 cyclophosphamide Drugs 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- 230000004580 weight loss Effects 0.000 description 18
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 16
- 230000002458 infectious effect Effects 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 150000008300 phosphoramidites Chemical class 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 230000003647 oxidation Effects 0.000 description 15
- 238000007254 oxidation reaction Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 14
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 14
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 14
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 14
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 14
- 230000008878 coupling Effects 0.000 description 14
- 238000010168 coupling process Methods 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000002777 nucleoside Substances 0.000 description 14
- 238000012545 processing Methods 0.000 description 14
- 238000000151 deposition Methods 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- 239000013642 negative control Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000008021 deposition Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 238000007912 intraperitoneal administration Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000282465 Canis Species 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 241000282324 Felis Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 241000315672 SARS coronavirus Species 0.000 description 7
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000000126 in silico method Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 210000003501 vero cell Anatomy 0.000 description 6
- 241000494545 Cordyline virus 2 Species 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 101001037140 Homo sapiens Immunoglobulin heavy variable 3-23 Proteins 0.000 description 5
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 5
- 102100040220 Immunoglobulin heavy variable 3-23 Human genes 0.000 description 5
- 241000699673 Mesocricetus auratus Species 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000005987 sulfurization reaction Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282836 Camelus dromedarius Species 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 description 4
- 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 description 4
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 4
- 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 description 4
- 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 description 4
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000013500 data storage Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000007306 functionalization reaction Methods 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 229940126662 negative allosteric modulator Drugs 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000002515 oligonucleotide synthesis Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000009736 wetting Methods 0.000 description 4
- QKDAMFXBOUOVMF-UHFFFAOYSA-N 4-hydroxy-n-(3-triethoxysilylpropyl)butanamide Chemical compound CCO[Si](OCC)(OCC)CCCNC(=O)CCCO QKDAMFXBOUOVMF-UHFFFAOYSA-N 0.000 description 3
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 3
- 244000303258 Annona diversifolia Species 0.000 description 3
- 235000002198 Annona diversifolia Nutrition 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102100031673 Corneodesmosin Human genes 0.000 description 3
- 101710139375 Corneodesmosin Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101001037139 Homo sapiens Immunoglobulin heavy variable 3-30 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241000482741 Human coronavirus NL63 Species 0.000 description 3
- 241001428935 Human coronavirus OC43 Species 0.000 description 3
- 102100040219 Immunoglobulin heavy variable 3-30 Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 229940125516 allosteric modulator Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 230000027832 depurination Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001806 memory b lymphocyte Anatomy 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 210000004160 naive b lymphocyte Anatomy 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- 108010000700 Acetolactate synthase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 241000282575 Gorilla Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101000998951 Homo sapiens Immunoglobulin heavy variable 1-8 Proteins 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102100036885 Immunoglobulin heavy variable 1-8 Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 241001504519 Papio ursinus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000282405 Pongo abelii Species 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- 108010019477 S-adenosyl-L-methionine-dependent N-methyltransferase Proteins 0.000 description 2
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 2
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002318 adhesion promoter Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000006642 detritylation reaction Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010228 ex vivo assay Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000007672 fourth generation sequencing Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000011553 hamster model Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002898 library design Methods 0.000 description 2
- 235000019689 luncheon sausage Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 108010000785 non-ribosomal peptide synthase Proteins 0.000 description 2
- 108010058731 nopaline synthase Proteins 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 229930001118 polyketide hybrid Natural products 0.000 description 2
- 125000003308 polyketide hybrid group Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000007841 sequencing by ligation Methods 0.000 description 2
- 150000004756 silanes Chemical class 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 230000007502 viral entry Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- WUHZCNHGBOHDKN-UHFFFAOYSA-N 11-triethoxysilylundecyl acetate Chemical compound CCO[Si](OCC)(OCC)CCCCCCCCCCCOC(C)=O WUHZCNHGBOHDKN-UHFFFAOYSA-N 0.000 description 1
- GVZJRBAUSGYWJI-UHFFFAOYSA-N 2,5-bis(3-dodecylthiophen-2-yl)thiophene Chemical compound C1=CSC(C=2SC(=CC=2)C2=C(C=CS2)CCCCCCCCCCCC)=C1CCCCCCCCCCCC GVZJRBAUSGYWJI-UHFFFAOYSA-N 0.000 description 1
- FOYWCEUVVIHJKD-UHFFFAOYSA-N 2-methyl-5-(1h-pyrazol-5-yl)pyridine Chemical compound C1=NC(C)=CC=C1C1=CC=NN1 FOYWCEUVVIHJKD-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 1
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108091005944 Cerulean Proteins 0.000 description 1
- 241000252506 Characiformes Species 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000289632 Dasypodidae Species 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 101000998950 Homo sapiens Immunoglobulin heavy variable 1-18 Proteins 0.000 description 1
- 101000998947 Homo sapiens Immunoglobulin heavy variable 1-46 Proteins 0.000 description 1
- 101001037141 Homo sapiens Immunoglobulin heavy variable 3-21 Proteins 0.000 description 1
- 101001037153 Homo sapiens Immunoglobulin heavy variable 3-7 Proteins 0.000 description 1
- 101000839687 Homo sapiens Immunoglobulin heavy variable 3-74 Proteins 0.000 description 1
- 101000839679 Homo sapiens Immunoglobulin heavy variable 4-39 Proteins 0.000 description 1
- 101000839781 Homo sapiens Immunoglobulin heavy variable 4-59 Proteins 0.000 description 1
- 101000989076 Homo sapiens Immunoglobulin heavy variable 4-61 Proteins 0.000 description 1
- 101001138130 Homo sapiens Immunoglobulin kappa variable 1-9 Proteins 0.000 description 1
- 101001047627 Homo sapiens Immunoglobulin kappa variable 2-28 Proteins 0.000 description 1
- 101001047617 Homo sapiens Immunoglobulin kappa variable 3-11 Proteins 0.000 description 1
- 101000604674 Homo sapiens Immunoglobulin kappa variable 4-1 Proteins 0.000 description 1
- 101001054843 Homo sapiens Immunoglobulin lambda variable 1-40 Proteins 0.000 description 1
- 101001054839 Homo sapiens Immunoglobulin lambda variable 1-51 Proteins 0.000 description 1
- 101000956885 Homo sapiens Immunoglobulin lambda variable 2-14 Proteins 0.000 description 1
- 101001005360 Homo sapiens Immunoglobulin lambda variable 3-1 Proteins 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102100036884 Immunoglobulin heavy variable 1-18 Human genes 0.000 description 1
- 102100036888 Immunoglobulin heavy variable 1-46 Human genes 0.000 description 1
- 102100040217 Immunoglobulin heavy variable 3-21 Human genes 0.000 description 1
- 102100040231 Immunoglobulin heavy variable 3-7 Human genes 0.000 description 1
- 102100028305 Immunoglobulin heavy variable 3-74 Human genes 0.000 description 1
- 102100028312 Immunoglobulin heavy variable 4-39 Human genes 0.000 description 1
- 102100028405 Immunoglobulin heavy variable 4-59 Human genes 0.000 description 1
- 102100029419 Immunoglobulin heavy variable 4-61 Human genes 0.000 description 1
- 102100020770 Immunoglobulin kappa variable 1-9 Human genes 0.000 description 1
- 102100022950 Immunoglobulin kappa variable 2-28 Human genes 0.000 description 1
- 102100022955 Immunoglobulin kappa variable 3-11 Human genes 0.000 description 1
- 102100038198 Immunoglobulin kappa variable 4-1 Human genes 0.000 description 1
- 102100026911 Immunoglobulin lambda variable 1-40 Human genes 0.000 description 1
- 102100026922 Immunoglobulin lambda variable 1-51 Human genes 0.000 description 1
- 102100038429 Immunoglobulin lambda variable 2-14 Human genes 0.000 description 1
- 102100025921 Immunoglobulin lambda variable 3-1 Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 244000261422 Lysimachia clethroides Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- NWSOKOJWKWNSAF-UHFFFAOYSA-N O=C(Sc1nnn[nH]1)c1ccccc1 Chemical compound O=C(Sc1nnn[nH]1)c1ccccc1 NWSOKOJWKWNSAF-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000002742 combinatorial mutagenesis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013499 data model Methods 0.000 description 1
- BAAAEEDPKUHLID-UHFFFAOYSA-N decyl(triethoxy)silane Chemical compound CCCCCCCCCC[Si](OCC)(OCC)OCC BAAAEEDPKUHLID-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229940126027 positive allosteric modulator Drugs 0.000 description 1
- 231100001271 preclinical toxicology Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000013639 protein trimer Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- AVXLXFZNRNUCRP-UHFFFAOYSA-N trichloro(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctyl)silane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[Si](Cl)(Cl)Cl AVXLXFZNRNUCRP-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- Coronaviruses like severe acute respiratory coronavirus 2 can cause severe respiratory problems.
- Therapies are needed for treating and preventing viral infection caused by coronaviruses like SARS-CoV-2.
- Antibodies possess the capability to bind with high specificity and affinity to biological targets.
- the design of therapeutic antibodies is challenging due to balancing of immunological effects with efficacy.
- nucleic acid libraries comprising: a plurality of sequences that when translated encode for antibodies or antibody fragments that bind to SARS-CoV-2 or ACE2 protein, wherein each of the sequences comprises a predetermined number of variants within a CDR relative to an input sequence that encodes an antibody, and wherein the library comprises at least 50,000 variant sequences.
- nucleic acid libraries wherein the antibodies or antibody fragments bind to a spike glycoprotein, a membrane protein, an envelope protein, a nucleocapsid protein, or combinations thereof of the SARS-CoV-2.
- nucleic acid libraries wherein the antibodies or antibody fragments bind to a spike glycoprotein.
- nucleic acid libraries wherein the antibodies or antibody fragment bind to a receptor binding domain of the spike glycoprotein. Further provided herein are nucleic acid libraries, wherein the library comprises at least 100,000 variant sequences. Further provided herein are nucleic acid libraries, wherein at least some of the sequences encode for an antibody light chain. Further provided herein are nucleic acid libraries, wherein at least some of the sequences encode for an antibody heavy chain. Further provided herein are nucleic acid libraries, wherein each sequence of the plurality of sequences comprises at least one variant in the CDR of a heavy chain or light chain relative to the input sequence.
- nucleic acid libraries wherein each sequence of the plurality of sequences comprises at least two variants in the CDR of a heavy chain or light chain relative to the input sequence. Further provided herein are nucleic acid libraries, wherein at least one of the variants is present in at least two individuals. Further provided herein are nucleic acid libraries, wherein at least one of the variants is present in at least three individuals. Further provided herein are nucleic acid libraries, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 5X higher binding affinity than a binding affinity of the input sequence. Further provided herein are nucleic acid libraries, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 25X higher binding affinity than a binding affinity of the input sequence.
- nucleic acid libraries wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 5 OX higher binding affinity than a binding affinity of the input sequence. Further provided herein are nucleic acid libraries, wherein each sequence of the plurality of sequences comprises at least one variant in the CDR of a heavy chain or light chain relative to a germline sequence of the input sequence. Further provided herein are nucleic acid libraries, wherein the CDR is a CDR1, CDR2, and CDR3 on a heavy chain. Further provided herein are nucleic acid libraries, wherein the CDR is a CDR1, CDR2, and CDR3 on a light chain.
- nucleic acid libraries wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having at least 70X higher binding affinity than the input sequence. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K D of less than 50 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K D of less than 25 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K D of less than 10 nM.
- nucleic acid libraries wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K D of less than 5 nM. Further provided herein are nucleic acid libraries, wherein the library encodes a CDR sequence of any one of SEQ ID NOs: 1-591.
- nucleic acid libraries comprising: a plurality of sequences that when translated encode for antibodies or antibody fragments that bind to a coronavirus or a receptor of the coronavirus, wherein each of the sequences comprises a predetermined number of variants within a CDR relative to an input sequence that encodes an antibody, and wherein the library comprises at least 50,000 variant sequences.
- the coronavirus is SARS- CoV, MERS-CoV, CoV-229E, HCoV-NL63, HCoV-OC43, or HCoV-HKUl.
- nucleic acid libraries wherein the receptor of the coronavirus is ACE2 or dipeptidyl peptidase 4 (DPP4). Further provided herein are nucleic acid libraries, wherein the library comprises at least 100,000 variant sequences. Further provided herein are nucleic acid libraries, wherein at least some of the sequences encode for an antibody light chain. Further provided herein are nucleic acid libraries, wherein at least some of the sequences encode for an antibody heavy chain. Further provided herein are nucleic acid libraries, wherein each sequence of the plurality of sequences comprises at least one variant in the CDR of a heavy chain or light chain relative to the input sequence.
- DPP4 dipeptidyl peptidase 4
- nucleic acid libraries wherein each sequence of the plurality of sequences comprises at least two variants in the CDR of a heavy chain or light chain relative to the input sequence. Further provided herein are nucleic acid libraries, wherein at least one of the variants is present in at least two individuals. Further provided herein are nucleic acid libraries, wherein at least one of the variants is present in at least three individuals. Further provided herein are nucleic acid libraries, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 5X higher binding affinity than a binding affinity of the input sequence. Further provided herein are nucleic acid libraries, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 25X higher binding affinity than a binding affinity of the input sequence.
- nucleic acid libraries wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 5 OX higher binding affinity than a binding affinity of the input sequence. Further provided herein are nucleic acid libraries, wherein each sequence of the plurality of sequences comprises at least one variant in the CDR of a heavy chain or light chain relative to a germline sequence of the input sequence. Further provided herein are nucleic acid libraries, wherein the CDR is a CDR1, CDR2, and CDR3 on a heavy chain. Further provided herein are nucleic acid libraries, wherein the CDR is a CDR1, CDR2, and CDR3 on a light chain.
- nucleic acid libraries wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having at least 70X higher binding affinity than the input sequence. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K D of less than 50 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K D of less than 25 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K D of less than 10 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K D of less than 5 nM.
- antibodies wherein the antibody comprises a sequence comprising at least 90% sequence identity to any one of SEQ ID NOs: 1-716.
- antibodies wherein the antibody comprises a sequence comprising at least 90% sequence identity to SEQ ID NOs: 1-716; and wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a single domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-id) antibody, or ab antigen-binding fragments thereof.
- scFv single chain antibody
- Fab fragment a F(ab')
- kits for treating a SARS-CoV-2 infection comprising administering the antibody as described herein.
- the antibody is administered prior to exposure to SARS-CoV-2.
- the antibody is administered at least about 1 week prior to exposure to SARS-CoV-2.
- the antibody is administered at least about 1 month prior to exposure to SARS-CoV-2.
- the antibody is administered at least about 5 months prior to exposure to SARS-CoV-2.
- the antibody is administered after exposure to SARS-CoV-2.
- the antibody is administered at most about 24 hours after exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at most about 1 week after exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at most about 1 month after exposure to SARS-CoV-2.
- kits for treating an individual with a SARS-CoV-2 infection with the antibody as described herein comprising: (a) obtaining or having obtained a sample from the individual; (b) performing or having performed an expression level assay on the sample to determine expression levels of SARS-CoV-2 antibodies; and (c) if the sample has an expression level of the SARS-CoV-2 antibodies then administering to the individual the antibody as described herein, thereby treating the SARS-CoV-2 infection.
- kits for optimizing an antibody comprising: (a) providing a plurality of polynucleotide sequences encoding for an antibody or antibody fragment, wherein the antibody or antibody fragment is derived from a subject having SARS-CoV-2; (b) generating a nucleic acid library comprising the plurality of sequences that when translated encode for antibodies or antibody fragments that bind SARS- CoV-2 or ACE2 protein, wherein each of the sequences comprises a predetermined number of variants within a CDR relative to an input sequence that encodes an antibody; wherein the library comprises at least 50,000 variant sequences; and (c) synthesizing the at least 50,000 variant sequences.
- the antibody library comprises at least 100,000 sequences. Further provided herein are methods, wherein the method further comprises enriching a subset of the variant sequences. Further provided herein are methods, wherein the method further comprises expressing the antibody or antibody fragments corresponding to the variant sequences. Further provided herein are methods, wherein the polynucleotide sequence is a murine, human, or chimeric antibody sequence. Further provided herein are methods, wherein each sequence of the plurality of variant sequences comprises at least one variant in each CDR of a heavy chain or light chain, relative to the input sequence. Further provided herein are methods, wherein each sequence of the plurality of variant sequences comprises at least two variants in each CDR of a heavy chain or light chain relative to the input sequence.
- nucleic acid library has a theoretical diversity of at least 10 10 sequences. Further provided herein are methods, wherein the nucleic acid library has a theoretical diversity of at least 10 12 sequences.
- antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-36 or 217-282; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 37-72 or 283-348; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 73-108 or 349-414; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 109-144 or 415-473; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs:
- antibodies or antibody fragments wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 30; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 66; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 102; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 138; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 174; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 210.
- antibodies or antibody fragments wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 35; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 71; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 107; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 143; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 179; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 215.
- antibodies or antibody fragments wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 12; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 48; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 84; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 120; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 156; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 192.
- antibodies or antibody fragments wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 31; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 67; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 103; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 139; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 175; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 211. Further provided herein are antibodies or antibody fragments, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 240;
- an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 306;
- an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 372;
- an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 437;
- an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 496; and
- an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 555.
- antibodies or antibody fragments wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 244; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 310; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 376; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 437; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 496; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 555.
- antibodies or antibody fragments wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 270; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 336; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 402; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 461; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 520; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 579. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment binds to a spike glycoprotein.
- antibodies or antibody fragments wherein the antibody or antibody fragment binds to a receptor binding domain of the spike glycoprotein. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K D of less than 50 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K D of less than 25 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K D of less than 10 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K D of less than 5 nM.
- antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 592-657, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 658-716.
- the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 594
- the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 660.
- antibodies or antibody fragments wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 595, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 661. Further provided herein are antibodies or antibody fragments, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO:
- VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 664.
- antibodies or antibody fragments wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO:
- VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 669.
- antibodies or antibody fragments wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO:
- VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 680.
- antibodies or antibody fragments wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO:
- VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 691.
- antibodies or antibody fragments wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO:
- the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 704.
- the antibody comprises a sequence comprising at least 90% sequence identity to any one of SEQ ID NOs: 1-716; and wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotyp
- nucleic acid compositions comprising: a) a first nucleic acid encoding a variable domain, heavy chain region (VH) comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 592-657; b) a second nucleic acid encoding a variable domain, light chain region (VL) comprising at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 658-716; and an excipient.
- VH variable domain, heavy chain region
- VL variable domain, light chain region
- kits for treating a SARS-CoV-2 infection comprising administering the antibody or antibody fragment described herein.
- the antibody is administered prior to exposure to SARS-CoV-2.
- the antibody is administered at least about 1 week prior to exposure to SARS-CoV-2.
- the antibody is administered at least about 1 month prior to exposure to SARS-CoV-2.
- the antibody is administered at least about 5 months prior to exposure to SARS-CoV-2.
- the antibody is administered after exposure to SARS-CoV-2.
- the antibody is administered at most about 24 hours after exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at most about 1 week after exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at most about 1 month after exposure to SARS-CoV-2.
- kits for treating an individual with a SARS-CoV-2 infection with the antibody or antibody fragment described herein comprising: a) obtaining or having obtained a sample from the individual; b) performing or having performed an expression level assay on the sample to determine expression levels of SARS-CoV-2 antibodies; and if the sample has an expression level of the SARS-CoV-2 antibodies then administering to the individual the antibody or antibody fragment described herein, thereby treating the SARS-CoV-2 infection.
- the antibody library comprises at least 100,000 sequences. Further provided herein are methods, wherein the method further comprises enriching a subset of the variant sequences. Further provided herein are methods, wherein the method further comprises expressing the antibody or antibody fragments corresponding to the variant sequences. Further provided herein are methods, wherein the polynucleotide sequence is a murine, human, or chimeric antibody sequence. Further provided herein are methods, wherein each sequence of the plurality of variant sequences comprises at least one variant in each CDR of a heavy chain or light chain, relative to the input sequence. Further provided herein are methods, wherein each sequence of the plurality of variant sequences comprises at least two variants in each CDR of a heavy chain or light chain relative to the input sequence.
- nucleic acid library has a theoretical diversity of at least 10 10 sequences. Further provided herein are methods, wherein the nucleic acid library has a theoretical diversity of at least 10 12 sequences.
- Figure 1 depicts a workflow for antibody optimization.
- Figure 2 presents a diagram of steps demonstrating an exemplary process workflow for gene synthesis as disclosed herein.
- Figure 3 illustrates an example of a computer system.
- Figure 4 is a block diagram illustrating an architecture of a computer system.
- Figure 5 is a diagram demonstrating a network configured to incorporate a plurality of computer systems, a plurality of cell phones and personal data assistants, and Network Attached Storage (NAS).
- NAS Network Attached Storage
- Figure 6 is a block diagram of a multiprocessor computer system using a shared virtual address memory space.
- Figure 7 is a schema of a panning workflow.
- Figures 8A-8B are graphs of panning data from round 4 for antibody 1.
- Figures 8C-8D are graphs of panning data from round 4 for antibody 2.
- Figures 9A-9B are graphs of panning data from round 4 for antibody 3.
- Figures 9C-9D are graphs of panning data from round 4 for antibody 4.
- Figure 10 shows graphs of ACE2 binding to SARS-CoV-2 variant antibodies.
- Figures 11A-11B are graphs of affinity data for SARS-CoV-2 variant antibodies.
- Figure 12 is a graph of binding of SARS-CoV-2 variant antibodies to S 1 protein.
- Figure 13A is a graph of SARS-CoV-2 and ACE2 competition ELISAs from a first set.
- Figure 13B is a graph of SARS-CoV-2 and ACE2 competition ELISAs from a first set showing
- Figures 14A-14B are graphs from a first set (FIG. 14A) and second set (FIG. 14B) showing ACE2 variant antibodies.
- Figures 14C-14D are graphs of SARS-CoV-2 variant antibodies in neutralization assays.
- Figure 15 is a graph of SARS-CoV-2 and ACE2 inhibition.
- Figures 16A-16B are graphs of SARS-CoV-2 variant antibodies on VERO E6 inhibition measured by FACS.
- Figure 17A is a graph of SARS-CoV-2 variant antibodies on VERO E6 inhibition measured by FACS as compared to CR3022.
- Figures 17B-17C are graphs of affinity of SARS-CoV-2 variant antibodies determined by coating ELISA plates with SARS-CoV-2 Spike Glycoprotein SI (FIG. 17B) or S protein trimer (Fig. 17C).
- Figure 17D is a graph of mean fluorescent intensity (MFI) plotted for each SARS-CoV-2 variant antibody dilution.
- Figures 18A-18C are graphs of mean fluorescent intensity (MFI) plotted for each SARS-CoV-2 variant antibody dilution.
- Figures 19A-19B are graphs of antibody kinetics for variants 2-5, 2-2, and 2-6 (FIG. 19A) and variants 1-12, 1-42, 1-20, and 1-19 (FIG. 19B).
- Figure 19C is a graph of percent neutralization for variants 1-12, 1-42 and 1-20.
- Figure 19D is a graph of percent neutralization for variants 1-12, 1-42 and 1-20 using live virus.
- Figures 20A-20D are graphs of variant antibodies neutralizing live virus.
- Figure 20E is a graph of variant antibodies neutralizing live virus FRNT.
- Figure 20F-20I show data of variant antibodies neutralizing live virus PRNT.
- Figure 21A shows a graph of percent weight change (y-axis) versus day post injection (PI, x- axis) for positive control convalescent plasma and negative control Mab c7dl 1.
- Figure 21B shows a graph of percent weight change (y-axis) versus day post injection (PI, x- axis) for variant antibody 6-63.
- Figure 21C shows a graph of percent weight change (y-axis) versus day post injection (PI, x- axis) for variant antibody 6-3.
- Figure 21D shows a graph of percent weight change (y-axis) versus day post injection (PI, x- axis) for variant antibody 6-36.
- Figure 21E shows graphs of percent weight change (y-axis) versus day post injection (PI, x- axis) based on dose.
- Figure 21F shows graphs of percent weight change (y-axis) versus day post injection (PI, x- axis) based on dose for variant antibodies 2-3, 2-63, and 1-20.
- Figure 21G shows a graph of data from a plaque assay to detect infectious virus in Day 9 lungs.
- the indicated antibodies were administered Day -1. Lungs were collected on Day 9, the right lobe was homogenized, clarified and supernatants were quantified by plaque titration. Individual hamster values are shown as symbols. White symbols indicate no infectious virus detected. The geometric mean PFU/gram is shown as bars. Limit of assay shown as dotted line.
- Figure 21H shows a graph of data from in situ hybridization (ISH) to detect infected cells in Day 9 lungs.
- the indicated antibodies were administered Day -1.
- Three animals per group were analyzed. Individual hamster values are shown as symbols.
- Median ISH scores are shown as bars.
- Figure 211 shows a graph of data from cumulative inflammation and edema scores for Day 9 lungs. The indicated antibodies were administered Day -1. Three animals per group were analyzed. Individual hamster cumulative pathology scores are shown as symbols. Median scores are shown as bars.
- Figure 22A shows a graph of the positive control pAb in a neutralization assay.
- Figure 22B shows a graph of neutralization of antibodies 6-63, 6-3, and 1-12 in VSV-SARS
- Figure 23A shows a graph of the positive control in a neutralization assay.
- Figures 23B-23C show graphs of neutralization by antibodies described herein.
- Figure 24B shows a graph of data from FIG. 24A plotted on one graph.
- Figure 24D shows a graph infectious vims in lungs of untreated control hamsters.
- CYP-treated animals were exposed to 1,000 pfu of vims by intranasal route on Day 0. Groups of four animals were euthanized and lungs were collected on the indicated days. Lung homogenates were assayed for infectious vims by plaque assay. Plaque forming units (PFU) per gram lung tissue are plotted. Geometric mean titers and SD are shown.
- nucleic acid encompasses double- or triple- stranded nucleic acids, as well as single-stranded molecules. In double- or triple -stranded nucleic acids, the nucleic acid strands need not be coextensive (i.e., a double-stranded nucleic acid need not be double- stranded along the entire length of both strands).
- Nucleic acid sequences when provided, are listed in the 5’ to 3’ direction, unless stated otherwise. Methods described herein provide for the generation of isolated nucleic acids. Methods described herein additionally provide for the generation of isolated and purified nucleic acids.
- a “nucleic acid” as referred to herein can comprise at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900,
- polypeptide-segments encoding nucleotide sequences, including sequences encoding non-ribosomal peptides (NRPs), sequences encoding non- ribosomal peptide -synthetase (NRPS) modules and synthetic variants, polypeptide segments of other modular proteins, such as antibodies, polypeptide segments from other protein families, including non coding DNA or RNA, such as regulatory sequences e.g.
- polynucleotides coding or non-coding regions of a gene or gene fragment, intergenic DNA, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short- hairpin RNA (shRNA), micro-RNA (miRNA), small nucleolar RNA, ribozymes, complementary DNA (cDNA), which is a DNA representation of mRNA, usually obtained by reverse transcription of messenger RNA (mRNA) or by amplification; DNA molecules produced synthetically or by amplification, genomic DNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence,
- the antibodies are optimized for SARS-CoV, MERS-CoV, CoV-229E, HCoV-NL63, HCoV-OC43, or HCoV-HKUl.
- the antibodies are optimized for SARS-CoV-2.
- the antibodies are optimized for a receptor that binds to the coronavirus.
- the receptor of the coronavirus is ACE2 or dipeptidyl peptidase 4 (DPP4).
- the antibodies are optimized based on interactions between the coronavirus and the receptor that binds the coronavirus.
- the antibodies are optimized for angiotensin-converting enzyme 2 (ACE2).
- ACE2 angiotensin-converting enzyme 2
- the antibodies are optimized based on interactions between SARS-CoV-2 and ACE2.
- Antibodies are in some instances optimized by the design of in-silico libraries comprising variant sequences of an input antibody sequence (FIG. 1).
- Input sequences 100 are in some instances modified in-silico 102 with one or more mutations or variants to generate libraries of optimized sequences 103.
- libraries are synthesized, cloned into expression vectors, and translation products (antibodies) evaluated for activity.
- fragments of sequences are synthesized and subsequently assembled.
- expression vectors are used to display and enrich desired antibodies, such as phage display. Selection pressures used during enrichment in some instances includes, but is not limited to, binding affinity, toxicity, immunological tolerance, stability, receptor-ligand competition, or developability.
- Such expression vectors allow antibodies with specific properties to be selected (“panning”), and subsequent propagation or amplification of such sequences enriches the library with these sequences. Panning rounds can be repeated any number of times, such as 1, 2, 3, 4, 5, 6, 7, or more than 7 rounds. Sequencing at one or more rounds is in some instances used to identify which sequences 105 have been enriched in the library.
- an antibody or antibody fragment sequence is used as input.
- the antibody sequence used as input is an antibody or antibody fragment sequence that binds SARS-CoV-2.
- the input is an antibody or antibody fragment sequence that binds a protein of SARS-CoV-2.
- the protein is a spike glycoprotein, a membrane protein, an envelope protein, a nucleocapsid protein, or combinations thereof.
- the protein is a spike glycoprotein of SARS-CoV-2.
- the protein is a receptor binding domain of SARS-CoV-2.
- the input sequence is an antibody or antibody fragment sequence that binds angiotensin-converting enzyme 2 (ACE2). In some instances, the input sequence is an antibody or antibody fragment sequence that binds an extracellular domain of the angiotensin-converting enzyme 2 (ACE2).
- a database 102 comprising known mutations or variants of one or more viruses is queried 101, and a library 103 of sequences comprising combinations of these mutations or variants are generated.
- the database comprises known mutations or variants of SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof.
- the database comprises known mutations or variants of the spike protein of SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof.
- the database comprises known mutations or variants of the receptor binding domain of SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof.
- the database comprises mutations or variants of a protein of SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof that binds to ACE2.
- the input sequence is a heavy chain sequence of an antibody or antibody fragment that binds SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof.
- the input sequence is a light chain sequence of an antibody or antibody fragment that binds SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof.
- the heavy chain sequence comprises varied CDR regions.
- the light chain sequence comprises varied CDR regions.
- known mutations or variants from CDRs are used to build the sequence library. Filters 104, or exclusion criteria, are in some instances used to select specific types of variants for members of the sequence library.
- sequences having a mutation or variant are added if a minimum number of organisms in the database have the mutation or variant.
- additional CDRs are specified for inclusion in the database.
- specific mutations or variants or combinations of mutations or variants are excluded from the library (e.g., known immunogenic sites, structure sites, etc.).
- specific sites in the input sequence are systematically replaced with histidine, aspartic acid, glutamic acid, or combinations thereof.
- the maximum or minimum number of mutations or variants allowed for each region of an antibody are specified. Mutations or variants in some instances are described relative to the input sequence or the input sequence’s corresponding germline sequence.
- sequences generated by the optimization comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more than 16 mutations or variants from the input sequence. In some instances, sequences generated by the optimization comprise no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or no more than 18 mutations or variants from the input sequence. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or about 18 mutations or variants relative to the input sequence. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a first CDR region. In some instances, sequences generated by the optimization comprise about
- sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a second CDR region. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a third CDR region. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a first CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a second CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a third CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a first CDR region of a light chain. In some instances, sequences generated by the optimization comprise about 1,
- sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a third CDR region of a light chain.
- a first CDR region is CDR1.
- a second CDR region is CDR2.
- a third CDR region is CDR3.
- In-silico antibodies libraries are in some instances synthesized, assembled, and enriched for desired sequences. [0076] The germline sequences corresponding to an input sequence may also be modified to generate sequences in a library.
- sequences generated by the optimization methods described herein comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more than 16 mutations or variants from the germline sequence.
- sequences generated by the optimization comprise no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or no more than 18 mutations or variants from the germline sequence.
- sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or about 18 mutations or variants relative to the germline sequence.
- Exemplary regions of the antibody include, but are not limited to, a complementarity-determining region (CDR), a variable domain, or a constant domain.
- the CDR is CDR1, CDR2, or CDR3.
- the CDR is a heavy domain including, but not limited to, CDRH1, CDRH2, and CDRH3.
- the CDR is a light domain including, but not limited to, CDRLl, CDRL2, and CDRL3.
- the variable domain is variable domain, light chain (VL) or variable domain, heavy chain (VH).
- the VL domain comprises kappa or lambda chains.
- the constant domain is constant domain, light chain (CL) or constant domain, heavy chain (CH).
- sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a first CDR region. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a second CDR region. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a third CDR region. In some instances, sequences generated by the optimization comprise about
- sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a first CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a second CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a third CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a first CDR region of a light chain. In some instances, sequences generated by the optimization comprise about 1,
- sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a third CDR region of a light chain.
- a first CDR region is CDR1.
- a second CDR region is CDR2.
- a third CDR region is CDR3.
- the antibodies or antibody fragments are single domain antibodies.
- Methods, compositions, and systems described herein for the optimization of antibodies comprise a ratio- variant approach that mirror the natural diversity of antibody sequences.
- libraries of optimized antibodies comprise variant antibody sequences.
- the variant antibody sequences are designed comprising variant CDR regions.
- the variant antibody sequences comprising variant CDR regions are generated by shuffling the natural CDR sequences in a llama, humanized, or chimeric framework.
- such libraries are synthesized, cloned into expression vectors, and translation products (antibodies) evaluated for activity.
- fragments of sequences are synthesized and subsequently assembled.
- expression vectors are used to display and enrich desired antibodies, such as phage display.
- the phage vector is a Fab phagemid vector.
- Selection pressures used during enrichment in some instances includes, but is not limited to, binding affinity, toxicity, immunological tolerance, stability, receptor-ligand competition, or developability.
- Such expression vectors allow antibodies with specific properties to be selected (“panning”), and subsequent propagation or amplification of such sequences enriches the library with these sequences. Panning rounds can be repeated any number of times, such as 1, 2, 3, 4, 5, 6, 7, or more than 7 rounds. In some instances, each round of panning involves a number of washes.
- each round of panning involves at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more than 16 washes.
- Described herein are methods and systems of in-silico library design. Libraries as described herein, in some instances, are designed based on a database comprising a variety of antibody sequences.
- the database comprises a plurality of variant antibody sequences against various targets.
- the database comprises at least 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more than 5000 antibody sequences.
- An exemplary database is an iCAN database.
- the database comprises naive and memory B-cell receptor sequences.
- the naive and memory B-cell receptor sequences are human, mouse, or primate sequences. In some instances, the naive and memory B-cell receptor sequences are human sequences. In some instances, the database is analyzed for position specific variation. In some instances, antibodies described herein comprise position specific variations in CDR regions. In some instances, the CDR regions comprise multiple sites for variation.
- Described herein are libraries comprising variation in a CDR region.
- the CDR is CDR1, CDR2, or CDR3 of a variable heavy chain.
- the CDR is CDR1, CDR2, or CDR3 of a variable light chain.
- the libraries comprise multiple variants encoding for CDR1, CDR2, or CDR3.
- the libraries as described herein encode for at least 50, 100,
- the libraries as described herein encode for at least 50, 100, 200, 300, 400, 500, 1000, 1200, 1500, 1700, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more than 5000 CDR1 sequences. In some instances, the libraries as described herein encode for at least 50, 100, 200, 300, 400, 500, 1000, 1200, 1500, 1700, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more than 5000 CDR2 sequences. In some instances, the libraries as described herein encode for at least 50, 100, 200, 300, 400, 500, 1000, 1200, 1500, 1700, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more than 5000 CDR3 sequences.
- In-silico antibodies libraries are in some instances synthesized, assembled, and enriched for desired sequences. [0082] Following synthesis of CDR1 variants, CDR2 variants, and CDR3 variants, in some instances, the CDR1 variants, the CDR2 variants, and the CDR3 variants are shuffled to generate a diverse library. In some instances, the diversity of the libraries generated by methods described herein have a theoretical diversity of at least or about 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 , 10 16 , 10 17 , 10 18 , or more than 10 18 sequences.
- the library has a final library diversity of at least or about 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 , 10 16 , 10 17 , 10 18 , or more than 10 18 sequences.
- sequences generated by methods described herein comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more than 16 mutations or variants from the germline sequence.
- sequences generated comprise no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or no more than 18 mutations or variants from the germline sequence.
- sequences generated comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or about 18 mutations or variants relative to the germline sequence.
- Antibodies described herein result in improved functional activity, structural stability, expression, specificity, or a combination thereof.
- kits for relating to SARS-CoV-2 binding libraries comprising nucleic acids encoding for a SARS-CoV-2 antibody.
- methods and compositions relating to ACE2 binding libraries comprising nucleic acids encoding for an ACE2 antibody. Such methods and compositions in some instances are generated by the antibody optimization methods and systems described herein.
- Libraries as described herein may be further variegated to provide for variant libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence.
- protein libraries that may be generated when the nucleic acid libraries are translated. In some instances, nucleic acid libraries as described herein are transferred into cells to generate a cell library.
- Downstream applications include identification of variant nucleic acids or protein sequences with enhanced biologically relevant functions, e.g., improved stability, affinity, binding, functional activity, and for the treatment or prevention of an infection caused by a coronavirus such as SARS-CoV-2.
- a coronavirus such as SARS-CoV-2.
- an antibody or antibody fragment described herein comprises a sequence of any one of SEQ ID NOs: 1-716. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a sequence of any one of SEQ ID NOs: 1-716. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a sequence of any one of SEQ ID NOs: 1-716. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-716. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a sequence of any one of SEQ ID NOs: 1-716.
- an antibody or antibody fragment described herein comprises a CDRH1 sequence of any one of SEQ ID NOs: 1-36 or 217-282. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-36 or 217-282. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-36 or 217-282. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-36 or 217-282.
- an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-36 or 217-282. In some instances, an antibody or antibody fragment described herein comprises a CDRH2 sequence of any one of SEQ ID NOs: 37-72 or 283-348. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH2 sequence of any one of SEQ ID NOs: 37-72 or 283-348. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH2 sequence of any one of SEQ ID NOs: 37-72 or 283-348.
- an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH2 sequence of any one of SEQ ID NOs: 37-72 or 283-348. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH2 sequence of any one of SEQ ID NOs: 37-72 or 283-348. In some instances, an antibody or antibody fragment described herein comprises a CDRH3 sequence of any one of SEQ ID NOs: 73-108 or 349-414. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH3 sequence of any one of SEQ ID NOs: 73-108 or 349-414.
- an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH3 sequence of any one of SEQ ID NOs: 73-108 or 349-414. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH3 sequence of any one of SEQ ID NOs: 73-108 or 349-414. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH3 sequence of any one of SEQ ID NOs: 73-108 or 349-414.
- an antibody or antibody fragment described herein comprises a CDRL1 sequence of any one of SEQ ID NOs: 109-144 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL1 sequence of any one of SEQ ID NOs: 109-144 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL1 sequence of any one of SEQ ID NOs: 109-144 or 415-473.
- an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL1 sequence of any one of SEQ ID NOs: 109-144 or 415- 473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL1 sequence of any one of SEQ ID NOs: 109-144 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a CDRL2 sequence of any one of SEQ ID NOs: 145-180 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL2 sequence of any one of SEQ ID NOs: 145- 180 or 415-473.
- an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL2 sequence of any one of SEQ ID NOs: 145-180 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL2 sequence of any one of SEQ ID NOs: 145-180 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL2 sequence of any one of SEQ ID NOs: 145-180 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a CDRL3 sequence of any one of SEQ ID NOs: 181-216, 442-456, or 532-546.
- an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL3 sequence of any one of SEQ ID NOs: 181-216 or 533- 591. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL3 sequence of any one of SEQ ID NOs: 181-216 or 533-591. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL3 sequence of any one of SEQ ID NOs: 181-216 or 533-591. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL3 sequence of any one of SEQ ID NOs: 181-216 or 533-591.
- the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-36 or 217-282; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 37-72 or 283-348; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 73-108 or 349-414; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 109-144 or 415-473; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs:
- the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 1-36 or 217-282; (b) an amino acid sequence of CDRH2 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 37-72 or 283-348; (c) an amino acid sequence of CDRH3 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 73-108 or 349-414; (d) an amino acid sequence of CDRL1 is at least or about 80%, 85%, 90%, or 9
- antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 592-657, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 658-716.
- VH variable domain, heavy chain region
- VL variable domain, light chain region
- the antibodies or antibody fragments comprise VH comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 592-657, and VL comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 658-716.
- sequence identity means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison.
- percentage of sequence identity is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- the term “homology” or “similarity” between two proteins is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one protein sequence to the second protein sequence. Similarity may be determined by procedures which are well-known in the art, for example, a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information).
- BLAST program Basic Local Alignment Search Tool at the National Center for Biological Information.
- Provided herein are libraries comprising nucleic acids encoding for SARS-CoV-2 antibodies. Antibodies described herein allow for improved stability for a range of SARS-CoV-2 or ACE2 binding domain encoding sequences. In some instances, the binding domain encoding sequences are determined by interactions between SARS-CoV-2 and ACE2.
- Sequences of binding domains based on surface interactions between SARS-CoV-2 and ACE2 are analyzed using various methods. For example, multispecies computational analysis is performed. In some instances, a structure analysis is performed. In some instances, a sequence analysis is performed. Sequence analysis can be performed using a database known in the art. Non-limiting examples of databases include, but are not limited to, NCBI BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi), UCSC Genome Browser (genome.ucsc.edu/), UniProt (www.uniprot.org/), and IUPHAR BPS Guide to PHARMACOLOGY (guidetopharmacology . org /) .
- SARS-CoV-2 or ACE2 binding domains designed based on sequence analysis among various organisms. For example, sequence analysis is performed to identify homologous sequences in different organisms. Exemplary organisms include, but are not limited to, mouse, rat, equine, sheep, cow, primate ( e.g chimpanzee, baboon, gorilla, orangutan, monkey), dog, cat, pig, donkey, rabbit, fish, fly, and human. In some instances, homologous sequences are identified in the same organism, across individuals.
- libraries comprising nucleic acids encoding for the SARS-CoV-2 or ACE2 binding domains may be generated.
- libraries of SARS-CoV-2 or ACE2 binding domains comprise sequences of SARS-CoV-2 or ACE2 binding domains designed based on conformational ligand interactions, peptide ligand interactions, small molecule ligand interactions, extracellular domains of SARS-CoV-2 or ACE2, or antibodies that target SARS-CoV-2 or ACE2.
- Libraries of SARS-CoV-2 or ACE2 binding domains may be translated to generate protein libraries.
- libraries of SARS-CoV-2 or ACE2 binding domains are translated to generate peptide libraries, immunoglobulin libraries, derivatives thereof, or combinations thereof. In some instances, libraries of SARS-CoV-2 or ACE2 binding domains are translated to generate protein libraries that are further modified to generate peptidomimetic libraries. In some instances, libraries of SARS-CoV-2 or ACE2 binding domains are translated to generate protein libraries that are used to generate small molecules.
- Methods described herein provide for synthesis of libraries of SARS-CoV-2 or ACE2 binding domains comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence.
- the predetermined reference sequence is a nucleic acid sequence encoding for a protein
- the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes.
- the libraries of SARS-CoV-2 or ACE2 binding domains comprise varied nucleic acids collectively encoding variations at multiple positions.
- the variant library comprises sequences encoding for variation of at least a single codon in a SARS-CoV-2 or ACE2 binding domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons in a SARS-CoV-2 or ACE2 binding domain.
- An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.
- Methods described herein provide for synthesis of libraries comprising nucleic acids encoding for the SARS-CoV-2 or ACE2 binding domains, wherein the libraries comprise sequences encoding for variation of length of the SARS-CoV-2 or ACE2 binding domains.
- the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons less as compared to a predetermined reference sequence.
- the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, or more than 300 codons more as compared to a predetermined reference sequence.
- antibodies may be designed and synthesized to comprise the SARS-CoV-2 or ACE2 binding domains.
- Antibodies comprising SARS-CoV-2 or ACE2 binding domains may be designed based on binding, specificity, stability, expression, folding, or downstream activity.
- the antibodies comprising SARS-CoV-2 or ACE2 binding domains enable contact with the SARS-CoV-2 or ACE2. In some instances, the antibodies comprising SARS-CoV-2 or ACE2 binding domains enables high affinity binding with the SARS-CoV-2 or ACE2.
- Exemplary amino acid sequences of SARS-CoV-2 or ACE2 binding domains comprise any one of SEQ ID NOs: 1-716.
- the SARS-CoV-2 antibody comprises a binding affinity (e.g., K D ) to SARS- CoV-2 of less than 1 nM, less than 1.2 nM, less than 2 nM, less than 5 nM, less than 10 nM, less than 11 nm, less than 13.5 nM, less than 15 nM, less than 20 nM, less than 25 nM, or less than 30 nM.
- the SARS-CoV-2 antibody comprises a K D of less than 1 nM.
- the SARS-CoV-2 antibody comprises a K D of less than 1.2 nM.
- the SARS-CoV-2 antibody comprises a K D of less than 2 nM. In some instances, the SARS-CoV-2 antibody comprises a K D of less than 5 nM. In some instances, the SARS-CoV-2 antibody comprises a K D of less than 10 nM. In some instances, the SARS- CoV-2 antibody comprises a K D of less than 13.5 nM. In some instances, the SARS-CoV-2 antibody comprises a K D of less than 15 nM. In some instances, the SARS-CoV-2 antibody comprises a K D of less than 20 nM. In some instances, the SARS-CoV-2 antibody comprises a K D of less than 25 nM. In some instances, the SARS-CoV-2 antibody comprises a K D of less than 30 nM.
- the ACE2 antibody comprises a binding affinity (e.g., K D ) to ACE2 of less than 1 nM, less than 1.2 nM, less than 2 nM, less than 5 nM, less than 10 nM, less than 11 nm, less than 13.5 nM, less than 15 nM, less than 20 nM, less than 25 nM, or less than 30 nM.
- the ACE2 antibody comprises a K D of less than 1 nM.
- the ACE2 antibody comprises a K D of less than 1.2 nM.
- the ACE2 antibody comprises a K D of less than 2 nM.
- the ACE2 antibody comprises a K D of less than 5 nM. In some instances, the ACE2 antibody comprises a K D of less than 10 nM. In some instances, the ACE2 antibody comprises a K D of less than 13.5 nM. In some instances, the ACE2 antibody comprises a K D of less than 15 nM. In some instances, the ACE2 antibody comprises a K D of less than 20 nM. In some instances, the ACE2 antibody comprises a K D of less than 25 nM. In some instances, the ACE2 antibody comprises a K D of less than 30 nM.
- the SARS-CoV-2 or ACE2 immunoglobulin is an agonist. In some instances, the SARS-CoV-2 or ACE2 immunoglobulin is an antagonist. In some instances, the SARS-CoV- 2 or ACE2 immunoglobulin is an allosteric modulator. In some instances, the allosteric modulator is a negative allosteric modulator. In some instances, the allosteric modulator is a positive allosteric modulator.
- the SARS-CoV-2 or ACE2 immunoglobulin results in agonistic, antagonistic, or allosteric effects at a concentration of at least or about 1 nM, 2 nM, 4 nM, 6 nM, 8 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 160 nM, 180 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, 1000 nM, or more than 1000 nM.
- the SARS-CoV-2 or ACE2 immunoglobulin is a negative allosteric modulator. In some instances, the SARS-CoV-2 or ACE2 immunoglobulin is a negative allosteric modulator at a concentration of at least or about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1 nM, 2 nM, 4 nM, 6 nM, 8 nM, 10 nM, 20 nM, 30 nM, 40 nM,
- the SARS-CoV-2 or ACE2 immunoglobulin is a negative allosteric modulator at a concentration in a range of about 0.001 to about 100, 0.01 to about 90, about 0.1 to about 80, 1 to about 50, about 10 to about 40 nM, or about 1 to about 10 nM.
- the SARS-CoV-2 or ACE2 immunoglobulin comprises an EC50 or IC50 of at least or about 0.001, 0.0025, 0.005, 0.01, 0.025, 0.05, 0.06, 0.07, 0.08, 0.9, 0.1, 0.5, 1, 2, 3, 4, 5, 6, or more than 6 nM.
- the SARS-CoV-2 or ACE2 immunoglobulin comprises an EC50 or IC50 of at least or about 1 nM, 2 nM, 4 nM, 6 nM, 8 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, or more than 100 nM.
- the affinity of the SARS-CoV-2 or ACE2 antibody generated by methods as described herein is at least or about 1.5x, 2.
- the SARS-CoV-2 or ACE2 antibody generated by methods as described herein is at least or about 1.5x, 2.
- the comparator antibody is an antibody with similar structure, sequence, or antigen target.
- SARS-CoV-2 or ACE2 binding libraries comprising nucleic acids encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains comprise variation in domain type, domain length, or residue variation.
- the domain is a region in the antibody comprising the SARS-CoV-2 or ACE2 binding domains.
- the region is the VH, CDRH3, or VL domain.
- the domain is the SARS-CoV-2 or ACE2 binding domain.
- Methods described herein provide for synthesis of a SARS-CoV-2 or ACE21 binding library of nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence.
- the predetermined reference sequence is a nucleic acid sequence encoding for a protein
- the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes.
- the SARS-CoV-2 or ACE2 binding library comprises varied nucleic acids collectively encoding variations at multiple positions.
- the variant library comprises sequences encoding for variation of at least a single codon of a VH or VL domain. In some instances, the variant library comprises sequences encoding for variation of at least a single codon in a SARS-CoV-2 or ACE2 binding domain. For example, at least one single codon of a SARS-CoV-2 or ACE2 binding domain is varied. In some instances, the variant library comprises sequences encoding for variation of multiple codons of a VH or VL domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons in a SARS-CoV-2 or ACE2 binding domain.
- An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.
- Methods described herein provide for synthesis of a SARS-CoV-2 or ACE2 binding library of nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence, wherein the SARS-CoV-2 or ACE2 binding library comprises sequences encoding for variation of length of a domain.
- the domain is VH or VL domain.
- the domain is the SARS-CoV-2 or ACE2binding domain.
- the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons less as compared to a predetermined reference sequence.
- the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, or more than 300 codons more as compared to a predetermined reference sequence.
- SARS-CoV-2 or ACE2 binding libraries comprising nucleic acids encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains, wherein the SARS-CoV-2 or ACE2 binding libraries are synthesized with various numbers of fragments. In some instances, the fragments comprise the VH or VL domain. In some instances, the SARS-CoV-2 or ACE2 binding libraries are synthesized with at least or about 2 fragments, 3 fragments, 4 fragments, 5 fragments, or more than 5 fragments.
- each of the nucleic acid fragments or average length of the nucleic acids synthesized may be at least or about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more than 600 base pairs. In some instances, the length is about 50 to 600, 75 to 575, 100 to 550, 125 to 525, 150 to 500, 175 to 475, 200 to 450, 225 to 425, 250 to 400, 275 to 375, or 300 to 350 base pairs.
- SARS-CoV-2 or ACE2 binding libraries comprising nucleic acids encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains as described herein comprise various lengths of amino acids when translated.
- the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids.
- the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 to about 75 amino acids.
- SARS-CoV-2 or ACE2 binding libraries comprising de novo synthesized variant sequences encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains comprise a number of variant sequences.
- a number of variant sequences is de novo synthesized for a CDRH1, CDRH2, CDRH3, CDRLl, CDRL2, CDRL3, VL, VH, or a combination thereof.
- a number of variant sequences is de novo synthesized for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4).
- a number of variant sequences are de novo synthesized for a SARS-CoV-2 or ACE2 binding domain.
- the number of variant sequences may be at least or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,
- the number of variant sequences is about 10 to 300, 25 to 275, 50 to 250, 75 to 225, 100 to 200, or 125 to 150 sequences.
- SARS-CoV-2 or ACE2 binding libraries comprising de novo synthesized variant sequences encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains comprise improved diversity.
- variants include affinity maturation variants.
- variants include variants in other regions of the antibody including, but not limited to, CDRH1, CDRH2, CDRLl, CDRL2, and CDRL3.
- the number of variants of the SARS-CoV-2 or ACE2 binding libraries is least or about 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 or more than 10 14 non identical sequences.
- libraries may be used for screening and analysis. For example, libraries are assayed for library displayability and panning. In some instances, displayability is assayed using a selectable tag.
- Exemplary tags include, but are not limited to, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, an affinity tag or other labels or tags that are known in the art. In some instances, the tag is histidine, polyhistidine, myc, hemagglutinin (HA), or FLAG.
- SARS-CoV-2 or ACE2 binding libraries comprise nucleic acids encoding antibodies comprising SARS-CoV-2 or ACE2 binding domains with multiple tags such as GFP, FLAG, and Lucy as well as a DNA barcode.
- libraries are assayed by sequencing using various methods including, but not limited to, single-molecule real-time (SMRT) sequencing, Polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis.
- SMRT single-molecule real-time
- the term antibody will be understood to include proteins having the characteristic two-armed, Y -shape of a typical antibody molecule as well as one or more fragments of an antibody that retain the ability to specifically bind to an antigen.
- Exemplary antibodies include, but are not limited to, a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv) (including fragments in which the VL and VH are joined using recombinant methods by a synthetic or natural linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules, including single chain Fab and scFab), a single chain antibody, a Fab fragment (including monovalent fragments comprising the VL, VH, CL, and CHI domain
- the libraries disclosed herein comprise nucleic acids encoding for an antibody, wherein the antibody is a Fv antibody, including Fv antibodies comprised of the minimum antibody fragment which contains a complete antigen- recognition and antigen-binding site.
- the Fv antibody consists of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association, and the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer.
- the six hypervariable regions confer antigen-binding specificity to the antibody.
- a single variable domain (or half of an Fv comprising only three hypervariable regions specific for an antigen, including single domain antibodies isolated from camelid animals comprising one heavy chain variable domain such as VHH antibodies or nanobodies) has the ability to recognize and bind antigen.
- the libraries disclosed herein comprise nucleic acids encoding for an antibody, wherein the antibody is a single-chain Fv or scFv, including antibody fragments comprising a VH, a VL, or both a VH and VL domain, wherein both domains are present in a single polypeptide chain.
- the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains allowing the scFv to form the desired structure for antigen binding.
- a scFv is linked to the Fc fragment or a VHH is linked to the Fc fragment (including minibodies).
- the antibody comprises immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, e.g., molecules that contain an antigen binding site.
- Immunoglobulin molecules are of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG 2, IgG 3, IgG 4, IgA 1 and IgA 2) or subclass.
- type e.g., IgG, IgE, IgM, IgD, IgA and IgY
- class e.g., IgG 1, IgG 2, IgG 3, IgG 4, IgA 1 and IgA 2 or subclass.
- the antibody is a multivalent antibody.
- the antibody is a monovalent, bivalent, or multivalent antibody.
- the antibody is monospecific, bispecific, or multispecific.
- the antibody is monovalent monospecific, monovalent bispecific, monovalent multispecific, bivalent monospecific, bivalent bispecific, bivalent multispecific, multivalent monospecific, multivalent bispecific, multivalent multispecific.
- the antibody is homodimeric, heterodimeric, or heterotrimeric.
- libraries comprise immunoglobulins that are adapted to the species of an intended therapeutic target.
- these methods include “mammalization” and comprises methods for transferring donor antigen-binding information to a less immunogenic mammal antibody acceptor to generate useful therapeutic treatments.
- the mammal is mouse, rat, equine, sheep, cow, primate (e.g., chimpanzee, baboon, gorilla, orangutan, monkey), dog, cat, pig, donkey, rabbit, and human.
- “Humanized” forms of non-human antibodies can be chimeric antibodies that contain minimal sequence derived from the non-human antibody.
- a humanized antibody is generally a human antibody (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody).
- the donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect.
- selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody.
- Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. In some instances, these modifications are made to further refine antibody performance.
- Caninization can comprise a method for transferring non-canine antigen-binding information from a donor antibody to a less immunogenic canine antibody acceptor to generate treatments useful as therapeutics in dogs.
- caninized forms of non-canine antibodies provided herein are chimeric antibodies that contain minimal sequence derived from non-canine antibodies.
- caninized antibodies are canine antibody sequences (“acceptor” or “recipient” antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non canine species (“donor” antibody) such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence, or an engineered sequence having the desired properties.
- donor antibody such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence, or an engineered sequence having the desired properties.
- donor antibody such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence,
- Felinization can comprise a method for transferring non-feline antigen-binding information from a donor antibody to a less immunogenic feline antibody acceptor to generate treatments useful as therapeutics in cats.
- felinized forms of non-feline antibodies provided herein are chimeric antibodies that contain minimal sequence derived from non-feline antibodies.
- felinized antibodies are feline antibody sequences (“acceptor” or “recipient” antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non- feline species (“donor” antibody) such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence, or an engineered sequence having the desired properties.
- donor antibody such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence, or an engineered sequence having the desired properties.
- donor antibody such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence
- the libraries comprise antibody mimetics.
- Exemplary antibody mimetics include, but are not limited to, anticalins, affilins, affibody molecules, affimers, affitins, alphabodies, avimers, atrimers, DARPins, fynomers, Kunitz domain-based proteins, monobodies, anticalins, knottins, armadillo repeat protein-based proteins, and bicyclic peptides.
- Libraries described herein comprising nucleic acids encoding for an antibody comprise variations in at least one region of the antibody.
- Exemplary regions of the antibody for variation include, but are not limited to, a complementarity-determining region (CDR), a variable domain, or a constant domain.
- the CDR is CDR1, CDR2, or CDR3.
- the CDR is a heavy domain including, but not limited to, CDRH1, CDRH2, and CDRH3.
- the CDR is a light domain including, but not limited to, CDRLl, CDRL2, and CDRL3.
- the variable domain is variable domain, light chain (VL) or variable domain, heavy chain (VH).
- the VL domain comprises kappa or lambda chains.
- the constant domain is constant domain, light chain (CL) or constant domain, heavy chain (CH).
- Methods described herein provide for synthesis of libraries comprising nucleic acids encoding an antibody, wherein each nucleic acid encodes for a predetermined variant of at least one predetermined reference nucleic acid sequence.
- the predetermined reference sequence is a nucleic acid sequence encoding for a protein
- the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes.
- the antibody library comprises varied nucleic acids collectively encoding variations at multiple positions.
- the variant library comprises sequences encoding for variation of at least a single codon of a CDRH1, CDRH2, CDRH3, CDRLl, CDRL2, CDRL3, VL, or VH domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of a CDRH1, CDRH2, CDRH3, CDRLl, CDRL2, CDRL3, VL, or VH domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of framework element 1 (LW1), framework element 2 (LW2), framework element 3 (FW3), or framework element 4 (LW4).
- LW1 framework element 1
- LW2 framework element 2
- FW3 framework element 3
- LW4 framework element 4
- An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.
- the at least one region of the antibody for variation is from heavy chain V- gene family, heavy chain D-gene family, heavy chain J-gene family, light chain V-gene family, or light chain J-gene family.
- the light chain V-gene family comprises immunoglobulin kappa (IGK) gene or immunoglobulin lambda (IGL).
- Exemplary regions of the antibody for variation include, but are not limited to, IGHV1-18, IGHV1-69, IGHV1-8, IGHV3-21, IGHV3-23, IGHV3-30/33m, IGHV3-28, IGHVl-69, IGHV3-74, IGHV4-39, IGHV4-59/61, IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3- 15, IGKV3-20, IGKV4-1, IGLV1-51, IGLV2-14, IGLV1-40, and IGLV3-1.
- the gene is IGHVl-69, IGHV3-30, IGHV3-23, IGHV3, IGHV1-46, IGHV3-7, IGHV1, or IGHV1-8. In some instances, the gene is IGHVl-69 and IGHV3-30. In some instances, the region of the antibody for variation is IGHJ3, IGHJ6, IGHJ, IGHJ4, IGHJ5, IGHJ2, or IGH1. In some instances, the region of the antibody for variation is IGHJ3, IGHJ6, IGHJ, or IGHJ4. In some instances, the at least one region of the antibody for variation is IGHV1-69, IGHV3-23, IGKV3-20, IGKV1-39, or combinations thereof.
- the at least one region of the antibody for variation is IGHV1-69 and IGKV3-20, In some instances, the at least one region of the antibody for variation is IGHV1-69 and IGKV1-39. In some instances, the at least one region of the antibody for variation is IGHV3-23 and IGKV3-20. In some instances, the at least one region of the antibody for variation is IGHV3-23 and IGKV1-39.
- the fragments comprise the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, or VH domain.
- the fragments comprise framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4).
- the antibody libraries are synthesized with at least or about 2 fragments, 3 fragments, 4 fragments, 5 fragments, or more than 5 fragments.
- each of the nucleic acid fragments or average length of the nucleic acids synthesized may be at least or about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more than 600 base pairs. In some instances, the length is about 50 to 600, 75 to 575, 100 to 550,
- Libraries comprising nucleic acids encoding for antibodies as described herein comprise various lengths of amino acids when translated.
- the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids.
- the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids.
- the length of the amino acid is about 22 amino acids to about 75 amino acids.
- the antibodies comprise at least or about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, or more than 5000 amino acids.
- a number of variant sequences for the at least one region of the antibody for variation are de novo synthesized using methods as described herein. In some instances, a number of variant sequences is de novo synthesized for CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or combinations thereof. In some instances, a number of variant sequences is de novo synthesized for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4).
- the number of variant sequences may be at least or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or more than 500 sequences.
- the number of variant sequences is at least or about 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, or more than 8000 sequences.
- the number of variant sequences is about 10 to 500, 25 to 475, 50 to 450, 75 to 425, 100 to 400, 125 to 375, 150 to 350, 175 to 325, 200 to 300, 225 to 375, 250 to 350, or 275 to 325 sequences.
- Variant sequences for the at least one region of the antibody vary in length or sequence.
- the at least one region that is de novo synthesized is for CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or combinations thereof.
- the at least one region that is de novo synthesized is for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4).
- the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or more than 50 variant nucleotides or amino acids as compared to wild-type.
- the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 additional nucleotides or amino acids as compared to wild-type. In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 less nucleotides or amino acids as compared to wild-type. In some instances, the libraries comprise at least or about 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , or more than 10 10 variants.
- antibody libraries may be used for screening and analysis.
- antibody libraries are assayed for library displayability and panning.
- displayability is assayed using a selectable tag.
- tags include, but are not limited to, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, an affinity tag or other labels or tags that are known in the art.
- the tag is histidine, polyhistidine, myc, hemagglutinin (HA), or FLAG.
- antibody libraries are assayed by sequencing using various methods including, but not limited to, single-molecule real-time (SMRT) sequencing, Polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis.
- SMRT single-molecule real-time
- Polony sequencing sequencing by ligation
- reversible terminator sequencing proton detection sequencing
- ion semiconductor sequencing nanopore sequencing
- electronic sequencing pyrosequencing
- Maxam-Gilbert sequencing Maxam-Gilbert sequencing
- chain termination e.g., Sanger sequencing
- +S sequencing e.g., +S sequencing, or sequencing by synthesis.
- antibody libraries are displayed on the surface of a cell or phage.
- antibody libraries are enriched for sequences with a desired activity using phage display.
- the antibody libraries are assayed for functional activity, structural stability (e.g., thermal stable or pH stable), expression, specificity, or a combination thereof.
- the antibody libraries are assayed for antibody capable of folding.
- a region of the antibody is assayed for functional activity, structural stability, expression, specificity, folding, or a combination thereof.
- a VH region or VL region is assayed for functional activity, structural stability, expression, specificity, folding, or a combination thereof.
- the affinity of antibodies or IgGs generated by methods as described herein is at least or about 1.5x, 2.
- the affinity of antibodies or IgGs generated by methods as described herein is at least or about 1.5x, 2.
- the comparator antibody is an antibody with similar structure, sequence, or antigen target.
- libraries comprising nucleic acids encoding for antibody comprising binding domains, wherein the libraries have improved specificity, stability, expression, folding, or downstream activity.
- libraries described herein are used for screening and analysis.
- libraries comprising nucleic acids encoding for antibody comprising binding domains, wherein the nucleic acid libraries are used for screening and analysis.
- screening and analysis comprises in vitro, in vivo, or ex vivo assays.
- Cells for screening include primary cells taken from living subjects or cell lines. Cells may be from prokaryotes (e.g., bacteria and fungi) or eukaryotes (e.g., animals and plants). Exemplary animal cells include, without limitation, those from a mouse, rabbit, primate, and insect.
- cells for screening include a cell line including, but not limited to, Chinese Hamster Ovary (CHO) cell line, human embryonic kidney (HEK) cell line, or baby hamster kidney (BHK) cell line.
- CHO Chinese Hamster Ovary
- HEK human embryonic kidney
- BHK baby hamster kidney
- nucleic acid libraries described herein may also be delivered to a multicellular organism.
- Exemplary multicellular organisms include, without limitation, a plant, a mouse, rabbit, primate, and insect.
- Nucleic acid libraries described herein may be screened for various pharmacological or pharmacokinetic properties.
- the libraries are screened using in vitro assays, in vivo assays, or ex vivo assays.
- in vitro pharmacological or pharmacokinetic properties include, but are not limited to, binding affinity, binding specificity, and binding avidity.
- Exemplary in vivo pharmacological or pharmacokinetic properties of libraries described herein that are screened include, but are not limited to, therapeutic efficacy, activity, preclinical toxicity properties, clinical efficacy properties, clinical toxicity properties, immunogenicity, potency, and clinical safety properties.
- nucleic acid libraries wherein the nucleic acid libraries may be expressed in a vector.
- Expression vectors for inserting nucleic acid libraries disclosed herein may comprise eukaryotic or prokaryotic expression vectors.
- Exemplary expression vectors include, without limitation, mammalian expression vectors: pSF-CMV-NEO-NH2-PPT-3XFLAG, pSF-CMV-NEO-COOH-3XFLAG, pSF-CMV- PURO-NH2-GST-TEV, pSF-OXB20-COOH-TEV-FLAG(R)-6His, pCEP4 pDEST27, pSF-CMV-Ub- KrYFP, pSF-CMV-FMDV-daGFP, pEFla-mCherry-Nl Vector, pEFla-tdTomato Vector, pSF-CMV- FMDV-Hygro, pSF-CMV-PGK-Puro, pMCP-tag(m), and pSF-CMV-PURO-NH2-CMYC; bacterial expression vectors: pSF-OXB20-BetaGal,pSF-OXB20-Fluc, pSF-O
- the vector is pcDNA3 or pcDNA3.1.
- Described herein are nucleic acid libraries that are expressed in a vector to generate a construct comprising an antibody.
- a size of the construct varies.
- the construct comprises at least or about 500, 600, 700, 800, 900, 1000, 1100, 1300, 1400, 1500, 1600, 1700, 1800, 2000, 2400, 2600, 2800, 3000, 3200, 3400, 3600, 3800, 4000, 4200,4400, 4600, 4800, 5000, 6000, 7000, 8000, 9000, 10000, or more than 10000 bases.
- a the construct comprises a range of about 300 to 1,000, 300 to 2,000, 300 to 3,000, 300 to 4,000, 300 to 5,000, 300 to 6,000, 300 to 7,000, 300 to 8,000, 300 to 9,000, 300 to 10,000, 1,000 to 2,000, 1,000 to 3,000, 1,000 to 4,000, 1,000 to 5,000, 1,000 to 6,000, 1,000 to 7,000, 1,000 to 8,000, 1,000 to 9,000, 1,000 to 10,000, 2,000 to 3,000, 2,000 to 4,000, 2,000 to 5,000, 2,000 to 6,000, 2,000 to 7,000, 2,000 to 8,000, 2,000 to 9,000, 2,000 to 10,000, 3,000 to 4,000, 3,000 to 5,000, 3,000 to 6,000, 3,000 to 7,000, 3,000 to 8,000, 3,000 to 9,000, 3,000 to 10,000, 4,000 to 5,000, 4,000 to 6,000, 3,000 to 6,000, 3,000 to 7,000, 3,000 to 8,000, 3,000 to 9,000, 3,000 to 10,000, 4,000 to 5,000, 4,000 to 6,000, 3,000 to 6,000, 3,000 to 7,000
- reporter genes include, but are not limited to, acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucuronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), cerulean fluorescent protein, citrine fluorescent protein, orange fluorescent protein , cherry fluorescent protein, turquoise fluorescent protein, blue fluorescent protein, horseradish peroxidase (HRP), luciferase (Fuc), nopaline synthase (NOS), octopine synthase (OCS), luciferase, and derivatives thereof.
- AHAS acetohydroxyacid synthase
- AP alkaline phosphatase
- LacZ beta galactosidase
- GUS beta glucuronidase
- CAT chloramphenicol
- Methods to determine modulation of a reporter gene include, but are not limited to, fluorometric methods (e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy), and antibiotic resistance determination.
- fluorometric methods e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy
- antibiotic resistance determination e.g. antibiotic resistance determination.
- SARS-CoV-2 or ACE2 binding libraries comprising nucleic acids encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains may have therapeutic effects.
- the SARS-CoV-2 or ACE2 binding libraries result in protein when translated that is used to treat a disease or disorder.
- the protein is an immunoglobulin.
- the protein is a peptidomimetic.
- the disease or disorder is a viral infection caused by SARS-CoV-2.
- the disease or disorder is a respiratory disease or disorder caused by SARS-CoV-2.
- SARS-CoV-2 or ACE2 variant antibody libraries as described herein may be used to treat SARS-CoV-2.
- the SARS-CoV-2 or ACE2 variant antibody libraries are used to treat or prevent symptoms of SARS-CoV-2. These symptoms include, but are not limited to, fever, chills, cough, fatigue, headaches, loss of taste, loss of smell, nausea, vomiting, muscle weakness, sleep difficulties, anxiety, and depression.
- the SARS-CoV-2 or ACE2 variant antibody libraries are used to treat a subject who has symptoms for an extended period of time. In some embodiments, the subject has symptoms for an extended period of time after testing negative for SARS-CoV-2.
- the subject has symptoms for an extended period of time including at least 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, or more than 1 year.
- the subject is a mammal.
- the subject is a mouse, rabbit, dog, or human.
- Subjects treated by methods described herein may be infants, adults, or children.
- Pharmaceutical compositions comprising antibodies or antibody fragments as described herein may be administered intravenously or subcutaneously.
- a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH1 sequence of any one of SEQ ID NOs: 217-266, 1495-1635, or 2059-2238. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH2 sequence of any one of SEQ ID NOs: 267-316, 1636-1776, or 2239-2418 In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH3 sequence of any one of SEQ ID NOs: 317-366, 1777-1917, or 2419-2598.
- a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-36 or 217-282; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 37-72 or 283- 348; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 73-108 or 349-414; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 109-144 or 415-473; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs:
- a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a VH comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 592-657, and VL comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 658-716.
- a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a heavy chain variable domain comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 1918-2058, 2599-2778, and 3095-3173.
- SARS-CoV-2 or ACE2 antibodies as described herein may confer immunity after exposure to SARS-CoV-2 or ACE2 antibodies.
- the SARS-CoV-2 or ACE2 antibodies described herein are used for passive immunization of a subject. In some instances, the subject is actively immunized after exposure to SARS-CoV-2 or ACE2 antibodies followed by exposure to SARS-CoV-2.
- SARS-CoV-2 or ACE2 antibodies are derived from a subject who has recovered from SARS- CoV-2.
- the immunity occurs at least about 30 minutes, 1 hour, 5 hours, 10 hours, 16 hours, 20 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, or more than 2 weeks after exposure to SARS-CoV-2 or ACE2 antibodies. In some instances, the immunity lasts for at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, or more than 5 years after exposure to SARS-CoV-2 or ACE2 antibodies.
- the subject receives the SARS-CoV-2 or ACE2 antibodies prior to exposure to SARS-CoV-2. In some embodiments, the subject receives the SARS-CoV-2 or ACE2 antibodies at least about 30 minutes, 1 hour, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, or more than 5 years prior to exposure to SARS-CoV-2.
- the subject receives the SARS- CoV-2 or ACE2 antibodies after exposure to SARS-CoV-2. In some embodiments, the subject receives the SARS-CoV-2 or ACE2 antibodies at least about 30 minutes, 1 hour, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, or more than 5 years after exposure to SARS-CoV-2.
- SARS-CoV-2 or ACE2 antibodies described herein may be administered through various routes.
- the administration may, depending on the composition being administered, for example, be oral, pulmonary, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal.
- compositions or pharmaceutical compositions comprising SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof that comprise various dosages of the antibodies or antibody fragment.
- the dosage is ranging from about 1 to 25 mg/kg, from about 1 to 50 mg/kg, from aboutl to 80 mg/kg, from about 1 to about 100 mg/kg, from about 5 to about 100 mg/kg, from about 5 to about 80 mg/kg, from about 5 to about 60 mg/kg, from about 5 to about 50 mg/kg or from about 5 to about 500 mg/kg which can be administered in single or multiple doses.
- the dosage is administered in an amount of about 0.01 mg/kg, about 0.05 mg/kg, about 0.10 mg/kg, about 0.25 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, about 100 mg/kg, about 105 mg/kg, about 110 mg/kg, about 115 mg/kg, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200, about 205
- SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof described herein improve disease severity.
- the SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof improve disease severity at a dose level of about 0.01 mg/kg, about 0.05 mg/kg, about 0.10 mg/kg, about 0.25 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, or about 20 mg/kg.
- the SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof improve disease severity at a dose level of about 1 mg/kg, about 5 mg/kg, or about 10 mg/kg.
- disease severity is determined by percent weight loss.
- the SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof protects against weight loss at a dose level of about 0.01 mg/kg, about 0.05 mg/kg, about 0.10 mg/kg, about 0.25 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, or about 20 mg/kg. In some embodiments, the SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof protects against weight loss at a dose level of about 1 mg/kg, about 5 mg/kg, or about 10 mg/kg. In some embodiments, SARS- CoV-2 or ACE2 antibodies or antibody fragment thereof [00147] Variant Libraries
- Variant nucleic acid libraries described herein may comprise a plurality of nucleic acids, wherein each nucleic acid encodes for a variant codon sequence compared to a reference nucleic acid sequence.
- each nucleic acid of a first nucleic acid population contains a variant at a single variant site.
- the first nucleic acid population contains a plurality of variants at a single variant site such that the first nucleic acid population contains more than one variant at the same variant site.
- the first nucleic acid population may comprise nucleic acids collectively encoding multiple codon variants at the same variant site.
- the first nucleic acid population may comprise nucleic acids collectively encoding up to 19 or more codons at the same position.
- the first nucleic acid population may comprise nucleic acids collectively encoding up to 60 variant triplets at the same position, or the first nucleic acid population may comprise nucleic acids collectively encoding up to 61 different triplets of codons at the same position.
- Each variant may encode for a codon that results in a different amino acid during translation.
- Table 1 provides a listing of each codon possible (and the representative amino acid) for a variant site.
- a nucleic acid population may comprise varied nucleic acids collectively encoding up to 20 codon variations at multiple positions.
- each nucleic acid in the population comprises variation for codons at more than one position in the same nucleic acid.
- each nucleic acid in the population comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more codons in a single nucleic acid.
- each variant long nucleic acid comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more codons in a single long nucleic acid.
- the variant nucleic acid population comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more codons in a single nucleic acid. In some instances, the variant nucleic acid population comprises variation for codons in at least about 10, 20, 30, 40, 50, 60, 70, 80, 90,
- a platform approach utilizing miniaturization, parallelization, and vertical integration of the end-to-end process from polynucleotide synthesis to gene assembly within nanowells on silicon to create a revolutionary synthesis platform.
- Devices described herein provide, with the same footprint as a 96-well plate, a silicon synthesis platform is capable of increasing throughput by a factor of up to 1,000 or more compared to traditional synthesis methods, with production of up to approximately 1,000,000 or more polynucleotides, or 10,000 or more genes in a single highly-parallelized run.
- Genomic information encoded in the DNA is transcribed into a message that is then translated into the protein that is the active product within a given biological pathway.
- Another exciting area of study is on the discovery, development and manufacturing of therapeutic molecules focused on a highly-specific cellular target. High diversity DNA sequence libraries are at the core of development pipelines for targeted therapeutics.
- Gene variants are used to express proteins in a design, build, and test protein engineering cycle that ideally culminates in an optimized gene for high expression of a protein with high affinity for its therapeutic target.
- Saturation mutagenesis in which a researcher attempts to generate all possible mutations or variants at a specific site within the receptor, represents one approach to this development challenge. Though costly and time and labor- intensive, it enables each variant to be introduced into each position. In contrast, combinatorial mutagenesis, where a few selected positions or short stretch of DNA may be modified extensively, generates an incomplete repertoire of variants with biased representation.
- a library with the desired variants available at the intended frequency in the right position available for testing — in other words, a precision library, enables reduced costs as well as turnaround time for screening.
- a drug itself can be optimized using methods described herein.
- a variant polynucleotide library encoding for a portion of the antibody is designed and synthesized.
- a variant nucleic acid library for the antibody can then be generated by processes described herein (e.g., PCR mutagenesis followed by insertion into a vector).
- the antibody is then expressed in a production cell line and screened for enhanced activity.
- Example screens include examining modulation in binding affinity to an antigen, stability, or effector function (e.g., ADCC, complement, or apoptosis).
- Exemplary regions to optimize the antibody include, without limitation, the Fc region, Fab region, variable region of the Fab region, constant region of the Fab region, variable domain of the heavy chain or light chain (VH or VL), and specific complementarity-determining regions (CDRs) of VH or V L .
- Nucleic acid libraries synthesized by methods described herein may be expressed in various cells associated with a disease state.
- Cells associated with a disease state include cell lines, tissue samples, primary cells from a subject, cultured cells expanded from a subject, or cells in a model system.
- Exemplary model systems include, without limitation, plant and animal models of a disease state.
- a variant nucleic acid library described herein is expressed in a cell associated with a disease state, or one in which a cell a disease state can be induced.
- an agent is used to induce a disease state in cells.
- Exemplary tools for disease state induction include, without limitation, a Cre/Lox recombination system, LPS inflammation induction, and streptozotocin to induce hypoglycemia.
- the cells associated with a disease state may be cells from a model system or cultured cells, as well as cells from a subject having a particular disease condition.
- Exemplary disease conditions include a bacterial, fungal, viral, autoimmune, or proliferative disorder (e.g., cancer).
- the variant nucleic acid library is expressed in the model system, cell line, or primary cells derived from a subject, and screened for changes in at least one cellular activity.
- Exemplary cellular activities include, without limitation, proliferation, cycle progression, cell death, adhesion, migration, reproduction, cell signaling, energy production, oxygen utilization, metabolic activity, and aging, response to free radical damage, or any combination thereof.
- Devices used as a surface for polynucleotide synthesis may be in the form of substrates which include, without limitation, homogenous array surfaces, patterned array surfaces, channels, beads, gels, and the like.
- substrates comprising a plurality of clusters, wherein each cluster comprises a plurality of loci that support the attachment and synthesis of polynucleotides.
- substrates comprise a homogenous array surface.
- the homogenous array surface is a homogenous plate.
- locus refers to a discrete region on a structure which provides support for polynucleotides encoding for a single predetermined sequence to extend from the surface.
- a locus is on a two dimensional surface, e.g. , a substantially planar surface. In some instances, a locus is on a three-dimensional surface, e.g., a well, microwell, channel, or post. In some instances, a surface of a locus comprises a material that is actively functionalized to attach to at least one nucleotide for polynucleotide synthesis, or preferably, a population of identical nucleotides for synthesis of a population of polynucleotides. In some instances, polynucleotide refers to a population of polynucleotides encoding for the same nucleic acid sequence.
- a surface of a substrate is inclusive of one or a plurality of surfaces of a substrate.
- the average error rates for polynucleotides synthesized within a library described here using the systems and methods provided are often less than 1 in 1000, less than about 1 in 2000, less than about 1 in 3000 or less often without error correction.
- a substrate provides support for the synthesis of more than 50, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2,000; 5,000; 10,000; 20,000; 50,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; 10,000,000 or more non-identical polynucleotides.
- the surfaces provide support for the synthesis of more than 50, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2,000; 5,000; 10,000; 20,000; 50,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; 10,000,000 or more polynucleotides encoding for distinct sequences.
- at least a portion of the polynucleotides have an identical sequence or are configured to be synthesized with an identical sequence.
- the substrate provides a surface environment for the growth of polynucleotides having at least 80, 90, 100, 120, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 bases or more.
- Provided herein are methods for polynucleotide synthesis on distinct loci of a substrate, wherein each locus supports the synthesis of a population of polynucleotides. In some cases, each locus supports the synthesis of a population of polynucleotides having a different sequence than a population of polynucleotides grown on another locus.
- each polynucleotide sequence is synthesized with 1, 2, 3, 4, 5, 6, 7, 8, 9 or more redundancy across different loci within the same cluster of loci on a surface for polynucleotide synthesis.
- the loci of a substrate are located within a plurality of clusters.
- a substrate comprises at least 10, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 20000, 30000, 40000, 50000 or more clusters.
- a substrate comprises more than 2,000; 5,000; 10,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,100,000; 1,200,000;
- a substrate comprises about 10,000 distinct loci.
- the amount of loci within a single cluster is varied in different instances.
- each cluster includes 1, 2, 3, 4, 5, 6, 7, 8, 9,
- each cluster includes about 50-500 loci. In some instances, each cluster includes about 100-200 loci. In some instances, each cluster includes about 100-150 loci. In some instances, each cluster includes about 109, 121, 130 or 137 loci. In some instances, each cluster includes about 19, 20, 61, 64 or more loci.
- polynucleotide synthesis occurs on a homogenous array surface.
- the number of distinct polynucleotides synthesized on a substrate is dependent on the number of distinct loci available in the substrate.
- the density of loci within a cluster or surface of a substrate is at least or about 1, 10, 25, 50, 65, 75, 100, 130, 150, 175, 200, 300, 400, 500, 1,000 or more loci per mm 2 .
- a substrate comprises 10-500, 25-400, 50-500, 100-500, 150-500, 10-250, 50-250, 10-200, or 50-200 mm 2 .
- the distance between the centers of two adjacent loci within a cluster or surface is from about 10-500, from about 10-200, or from about 10-100 um.
- the distance between two centers of adjacent loci is greater than about 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 um. In some instances, the distance between the centers of two adjacent loci is less than about 200, 150, 100, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, each locus has a width of about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 um. In some cases, each locus has a width of about 0.5-100, 0.5-50, 10-75, or 0.5-50 um.
- the density of clusters within a substrate is at least or about 1 cluster per 100 mm 2 , 1 cluster per 10 mm 2 , 1 cluster per 5 mm 2 , 1 cluster per 4 mm 2 , 1 cluster per 3 mm 2 , 1 cluster per 2 mm 2 , 1 cluster per 1 mm 2 , 2 clusters per 1 mm 2 , 3 clusters per 1 mm 2 , 4 clusters per 1 mm 2 , 5 clusters per 1 mm 2 , 10 clusters per 1 mm 2 , 50 clusters per 1 mm 2 or more.
- a substrate comprises from about 1 cluster per 10 mm 2 to about 10 clusters per 1 mm 2 .
- the distance between the centers of two adjacent clusters is at least or about 50, 100, 200, 500, 1000, 2000, or 5000 um. In some cases, the distance between the centers of two adjacent clusters is between about 50-100, 50-200, 50-300, 50-500, and 100-2000 um. In some cases, the distance between the centers of two adjacent clusters is between about 0.05-50, 0.05-10, 0.05-5, 0.05-4, 0.05-3, 0.05-2, 0.1-10, 0.2-10, 0.3-10, 0.4-10, 0.5-10, 0.5-5, or 0.5-2 mm. In some cases, each cluster has a cross section of about 0.5 to about 2, about 0.5 to about 1, or about 1 to about 2 mm.
- each cluster has a cross section of about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 mm. In some cases, each cluster has an interior cross section of about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 mm.
- a substrate is about the size of a standard 96 well plate, for example between about 100 and about 200 mm by between about 50 and about 150 mm.
- a substrate has a diameter less than or equal to about 1000, 500, 450, 400, 300, 250, 200, 150, 100 or 50 mm.
- the diameter of a substrate is between about 25-1000, 25-800, 25-600, 25-500, 25-400, 25-300, or 25-200 mm.
- a substrate has a planar surface area of at least about 100; 200; 500; 1,000; 2,000; 5,000; 10,000; 12,000; 15,000; 20,000; 30,000; 40,000; 50,000 mm 2 or more.
- the thickness of a substrate is between about 50- 2000, 50- 1000, 100-1000, 200-1000, or 250-1000 mm.
- Substrates, devices, and reactors provided herein are fabricated from any variety of materials suitable for the methods, compositions, and systems described herein.
- substrate materials are fabricated to exhibit a low level of nucleotide binding.
- substrate materials are modified to generate distinct surfaces that exhibit a high level of nucleotide binding.
- substrate materials are transparent to visible and/or UV light.
- substrate materials are sufficiently conductive, e.g., are able to form uniform electric fields across all or a portion of a substrate.
- conductive materials are connected to an electric ground.
- the substrate is heat conductive or insulated.
- a substrate comprises flexible materials.
- materials can include, without limitation: nylon, both modified and unmodified, nitrocellulose, polypropylene, and the like.
- a substrate comprises rigid materials.
- materials can include, without limitation: glass; fuse silica; silicon, plastics (for example polytetrafluoroethylene, polypropylene, polystyrene, polycarbonate, and blends thereof, and the like); metals (for example, gold, platinum, and the like).
- the substrate, solid support or reactors can be fabricated from a material selected from the group consisting of silicon, polystyrene, agarose, dextran, cellulosic polymers, polyacrylamides, polydimethylsiloxane (PDMS), and glass.
- the substrates/solid supports or the microstructures, reactors therein may be manufactured with a combination of materials listed herein or any other suitable material known in the art.
- a substrate for the methods, compositions, and systems described herein, wherein the substrates have a surface architecture suitable for the methods, compositions, and systems described herein.
- a substrate comprises raised and/or lowered features.
- One benefit of having such features is an increase in surface area to support polynucleotide synthesis.
- a substrate having raised and/or lowered features is referred to as a three-dimensional substrate.
- a three-dimensional substrate comprises one or more channels.
- one or more loci comprise a channel.
- the channels are accessible to reagent deposition via a deposition device such as a material deposition device.
- reagents and/or fluids collect in a larger well in fluid communication one or more channels.
- a substrate comprises a plurality of channels corresponding to a plurality of loci with a cluster, and the plurality of channels are in fluid communication with one well of the cluster.
- a library of polynucleotides is synthesized in a plurality of loci of a cluster.
- substrates for the methods, compositions, and systems described herein wherein the substrates are configured for polynucleotide synthesis.
- the structure is configured to allow for controlled flow and mass transfer paths for polynucleotide synthesis on a surface.
- the configuration of a substrate allows for the controlled and even distribution of mass transfer paths, chemical exposure times, and/or wash efficacy during polynucleotide synthesis.
- the configuration of a substrate allows for increased sweep efficiency, for example by providing sufficient volume for a growing polynucleotide such that the excluded volume by the growing polynucleotide does not take up more than 50, 45, 40, 35, 30, 25, 20, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1%, or less of the initially available volume that is available or suitable for growing the polynucleotide.
- a three-dimensional structure allows for managed flow of fluid to allow for the rapid exchange of chemical exposure.
- substrates for the methods, compositions, and systems described herein wherein the substrates comprise structures suitable for the methods, compositions, and systems described herein.
- segregation is achieved by physical structure.
- segregation is achieved by differential functionalization of the surface generating active and passive regions for polynucleotide synthesis.
- differential functionalization is achieved by alternating the hydrophobicity across the substrate surface, thereby creating water contact angle effects that cause beading or wetting of the deposited reagents.
- Employing larger structures can decrease splashing and cross contamination of distinct polynucleotide synthesis locations with reagents of the neighboring spots.
- a device such as a material deposition device, is used to deposit reagents to distinct polynucleotide synthesis locations.
- Substrates having three-dimensional features are configured in a manner that allows for the synthesis of a large number of polynucleotides (e.g ., more than about 10,000) with a low error rate (e.g., less than about 1:500, 1:1000, 1:1500, 1:2,000, 1:3,000, 1:5,000, or 1:10,000).
- a substrate comprises features with a density of about or greater than about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400 or 500 features per mm 2 .
- a well of a substrate may have the same or different width, height, and/or volume as another well of the substrate.
- a channel of a substrate may have the same or different width, height, and/or volume as another channel of the substrate.
- the diameter of a cluster or the diameter of a well comprising a cluster, or both is between about 0.05-50, 0.05-10, 0.05-5, 0.05-4, 0.05-3, 0.05-2, 0.05-1, 0.05- 0.5, 0.05-0.1, 0.1-10, 0.2-10, 0.3-10, 0.4-10, 0.5-10, 0.5-5, or 0.5-2 mm.
- the diameter of a cluster or well or both is less than or about 5, 4, 3, 2, 1, 0.5, 0.1, 0.09, 0.08, 0.07, 0.06, or 0.05 mm. In some instances, the diameter of a cluster or well or both is between about 1.0 and 1.3 mm. In some instances, the diameter of a cluster or well, or both is about 1.150 mm. In some instances, the diameter of a cluster or well, or both is about 0.08 mm.
- the diameter of a cluster refers to clusters within a two- dimensional or three-dimensional substrate.
- the height of a well is from about 20-1000, 50-1000, 100- 1000, 200-1000, 300-1000, 400-1000, or 500-1000 um. In some cases, the height of a well is less than about 1000, 900, 800, 700, or 600 um.
- a substrate comprises a plurality of channels corresponding to a plurality of loci within a cluster, wherein the height or depth of a channel is 5-500, 5-400, 5-300, 5-200, 5-100, 5-50, or 10-50 um. In some cases, the height of a channel is less than 100, 80, 60, 40, or 20 um.
- the diameter of a channel, locus (e.g. , in a substantially planar substrate) or both channel and locus (e.g., in a three-dimensional substrate wherein a locus corresponds to a channel) is from about 1-1000, 1-500, 1-200, 1-100, 5-100, or 10-100 um, for example, about 90, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, the diameter of a channel, locus, or both channel and locus is less than about 100, 90, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, the distance between the center of two adjacent channels, loci, or channels and loci is from about 1-500, 1-200, 1-100, 5-200, 5-100, 5-50, or 5-30, for example, about 20 um.
- the surface comprises various surface modifications.
- the surface modifications are employed for the chemical and/or physical alteration of a surface by an additive or subtractive process to change one or more chemical and/or physical properties of a substrate surface or a selected site or region of a substrate surface.
- surface modifications include, without limitation, (1) changing the wetting properties of a surface, (2) functionalizing a surface, i.e., providing, modifying or substituting surface functional groups, (3) defunctionalizing a surface, i.e., removing surface functional groups, (4) otherwise altering the chemical composition of a surface, e.g., through etching, (5) increasing or decreasing surface roughness, (6) providing a coating on a surface, e.g., a coating that exhibits wetting properties that are different from the wetting properties of the surface, and/or (7) depositing particulates on a surface.
- adhesion promoter facilitates structured patterning of loci on a surface of a substrate.
- exemplary surfaces for application of adhesion promotion include, without limitation, glass, silicon, silicon dioxide and silicon nitride.
- the adhesion promoter is a chemical with a high surface energy.
- a second chemical layer is deposited on a surface of a substrate.
- the second chemical layer has a low surface energy.
- surface energy of a chemical layer coated on a surface supports localization of droplets on the surface. Depending on the patterning arrangement selected, the proximity of loci and/or area of fluid contact at the loci are alterable.
- a substrate surface, or resolved loci, onto which nucleic acids or other moieties are deposited, e.g., for polynucleotide synthesis are smooth or substantially planar (e.g., two- dimensional) or have irregularities, such as raised or lowered features (e.g., three-dimensional features).
- a substrate surface is modified with one or more different layers of compounds.
- modification layers of interest include, without limitation, inorganic and organic layers such as metals, metal oxides, polymers, small organic molecules and the like.
- resolved loci of a substrate are functionalized with one or more moieties that increase and/or decrease surface energy.
- a moiety is chemically inert.
- a moiety is configured to support a desired chemical reaction, for example, one or more processes in a polynucleotide synthesis reaction.
- the surface energy, or hydrophobicity, of a surface is a factor for determining the affinity of a nucleotide to attach onto the surface.
- a method for substrate functionalization comprises: (a) providing a substrate having a surface that comprises silicon dioxide; and (b) silanizing the surface using, a suitable silanizing agent described herein or otherwise known in the art, for example, an organofunctional alkoxysilane molecule.
- a suitable silanizing agent described herein or otherwise known in the art, for example, an organofunctional alkoxysilane molecule.
- a substrate surface is functionalized by contact with a derivatizing composition that contains a mixture of silanes, under reaction conditions effective to couple the silanes to the substrate surface, typically via reactive hydrophilic moieties present on the substrate surface.
- Silanization generally covers a surface through self-assembly with organofunctional alkoxysilane molecules.
- a variety of siloxane functionalizing reagents can further be used as currently known in the art, e.g., for lowering or increasing surface energy.
- the organofunctional alkoxysilanes are classified according to their organic functions.
- Methods of the current disclosure for polynucleotide synthesis may include processes involving phosphoramidite chemistry.
- polynucleotide synthesis comprises coupling a base with phosphoramidite.
- Polynucleotide synthesis may comprise coupling a base by deposition of phosphoramidite under coupling conditions, wherein the same base is optionally deposited with phosphoramidite more than once, i.e., double coupling.
- Polynucleotide synthesis may comprise capping of unreacted sites. In some instances, capping is optional.
- Polynucleotide synthesis may also comprise oxidation or an oxidation step or oxidation steps.
- Polynucleotide synthesis may comprise deblocking, detritylation, and sulfurization. In some instances, polynucleotide synthesis comprises either oxidation or sulfurization. In some instances, between one or each step during a polynucleotide synthesis reaction, the device is washed, for example, using tetrazole or acetonitrile. Time frames for any one step in a phosphoramidite synthesis method may be less than about 2 min, 1 min, 50 sec, 40 sec, 30 sec, 20 sec and 10 sec.
- Polynucleotide synthesis using a phosphoramidite method may comprise a subsequent addition of a phosphoramidite building block (e.g., nucleoside phosphoramidite) to a growing polynucleotide chain for the formation of a phosphite triester linkage.
- a phosphoramidite building block e.g., nucleoside phosphoramidite
- Phosphoramidite polynucleotide synthesis proceeds in the 3’ to 5’ direction.
- Phosphoramidite polynucleotide synthesis allows for the controlled addition of one nucleotide to a growing nucleic acid chain per synthesis cycle. In some instances, each synthesis cycle comprises a coupling step.
- Phosphoramidite coupling involves the formation of a phosphite triester linkage between an activated nucleoside phosphoramidite and a nucleoside bound to the substrate, for example, via a linker.
- the nucleoside phosphoramidite is provided to the device activated.
- the nucleoside phosphoramidite is provided to the device with an activator.
- nucleoside phosphoramidites are provided to the device in a 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100-fold excess or more over the substrate-bound nucleosides.
- nucleoside phosphoramidite is performed in an anhydrous environment, for example, in anhydrous acetonitrile.
- the device is optionally washed.
- the coupling step is repeated one or more additional times, optionally with a wash step between nucleoside phosphoramidite additions to the substrate.
- a polynucleotide synthesis method used herein comprises 1, 2, 3 or more sequential coupling steps.
- the nucleoside bound to the device is de-protected by removal of a protecting group, where the protecting group functions to prevent polymerization.
- a common protecting group is 4,4’-dimethoxytrityl (DMT).
- phosphoramidite polynucleotide synthesis methods optionally comprise a capping step.
- a capping step the growing polynucleotide is treated with a capping agent.
- a capping step is useful to block unreacted substrate-bound 5 ’-OH groups after coupling from further chain elongation, preventing the formation of polynucleotides with internal base deletions.
- phosphoramidites activated with lH-tetrazole may react, to a small extent, with the 06 position of guanosine. Without being bound by theory, upon oxidation with F /water, this side product, possibly via 06-N7 migration, may undergo depurination.
- the apurinic sites may end up being cleaved in the course of the final deprotection of the polynucleotide thus reducing the yield of the full-length product.
- the 06 modifications may be removed by treatment with the capping reagent prior to oxidation with F/watcr.
- inclusion of a capping step during polynucleotide synthesis decreases the error rate as compared to synthesis without capping.
- the capping step comprises treating the substrate-bound polynucleotide with a mixture of acetic anhydride and 1-methylimidazole. Following a capping step, the device is optionally washed.
- the device bound growing nucleic acid is oxidized.
- the oxidation step comprises the phosphite triester is oxidized into a tetracoordinated phosphate triester, a protected precursor of the naturally occurring phosphate diester intemucleoside linkage.
- oxidation of the growing polynucleotide is achieved by treatment with iodine and water, optionally in the presence of a weak base (e.g., pyridine, lutidine, collidine). Oxidation may be carried out under anhydrous conditions using, e.g.
- a capping step is performed following oxidation.
- a second capping step allows for device drying, as residual water from oxidation that may persist can inhibit subsequent coupling.
- the device and growing polynucleotide is optionally washed.
- the step of oxidation is substituted with a sulfurization step to obtain polynucleotide phosphorothioates, wherein any capping steps can be performed after the sulfurization.
- reagents are capable of the efficient sulfur transfer, including but not limited to 3-(Dimethylaminomethylidene)amino)-3H-l,2,4-dithiazole-3-thione, DDTT, 3H-l,2-benzodithiol-3-one 1,1- dioxide, also known as Beaucage reagent, and N,N,N'N'-Tetraethylthiuram disulfide (TETD).
- DDTT 3-(Dimethylaminomethylidene)amino)-3H-l,2,4-dithiazole-3-thione
- DDTT 3H-l,2-benzodithiol-3-one 1,1- dioxide
- Beaucage reagent also known as Beaucage reagent
- TETD N,N,N'N'-Tetraethylthiuram disulfide
- the protected 5 ’ end of the device bound growing polynucleotide is removed so that the primary hydroxyl group is reactive with a next nucleoside phosphoramidite.
- the protecting group is DMT and deblocking occurs with trichloroacetic acid in dichloromethane. Conducting detritylation for an extended time or with stronger than recommended solutions of acids may lead to increased depurination of solid support-bound polynucleotide and thus reduces the yield of the desired full-length product.
- Methods and compositions of the disclosure described herein provide for controlled deblocking conditions limiting undesired depurination reactions.
- the device bound polynucleotide is washed after deblocking. In some instances, efficient washing after deblocking contributes to synthesized polynucleotides having a low error rate.
- Methods for the synthesis of polynucleotides typically involve an iterating sequence of the following steps: application of a protected monomer to an actively functionalized surface (e.g. , locus) to link with either the activated surface, a linker or with a previously deprotected monomer; deprotection of the applied monomer so that it is reactive with a subsequently applied protected monomer; and application of another protected monomer for linking.
- One or more intermediate steps include oxidation or sulfurization.
- one or more wash steps precede or follow one or all of the steps.
- Methods for phosphoramidite-based polynucleotide synthesis comprise a series of chemical steps.
- one or more steps of a synthesis method involve reagent cycling, where one or more steps of the method comprise application to the device of a reagent useful for the step.
- reagents are cycled by a series of liquid deposition and vacuum drying steps.
- substrates comprising three-dimensional features such as wells, microwells, channels and the like, reagents are optionally passed through one or more regions of the device via the wells and/or channels.
- Methods and systems described herein relate to polynucleotide synthesis devices for the synthesis of polynucleotides. The synthesis may be in parallel. For example, at least or about at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 100, 150, 200,
- polynucleotides can be synthesized in parallel.
- the total number polynucleotides that may be synthesized in parallel may be from 2-100000, 3-50000, 4-10000, 5-1000, 6-900, 7-850, 8-800, 9-750, 10- 700, 11-650, 12-600, 13-550, 14-500, 15-450, 16-400, 17-350, 18-300, 19-250, 20-200, 21-150,22-100, 23- 50, 24-45, 25-40, 30-35.
- total number of polynucleotides synthesized in parallel may fall within any range bound by any of these values, for example 25-100.
- the total number of polynucleotides synthesized in parallel may fall within any range defined by any of the values serving as endpoints of the range.
- Total molar mass of polynucleotides synthesized within the device or the molar mass of each of the polynucleotides may be at least or at least about 10, 20, 30, 40, 50, 100,
- the length of each of the polynucleotides or average length of the polynucleotides within the device may be at least or about at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 400, 500 nucleotides, or more.
- the length of each of the polynucleotides or average length of the polynucleotides within the device may be at most or about at most 500, 400, 300, 200, 150, 100, 50, 45, 35, 30, 25, 20, 19,
- the length of each of the polynucleotides or average length of the polynucleotides within the device may fall from 10-500, 9-400, 11-300, 12-200, 13-150, 14- 100, 15-50, 16-45, 17-40, 18-35, 19-25.
- the length of each of the polynucleotides or average length of the polynucleotides within the device may fall within any range bound by any of these values, for example 100-300.
- the length of each of the polynucleotides or average length of the polynucleotides within the device may fall within any range defined by any of the values serving as endpoints of the range.
- Methods for polynucleotide synthesis on a surface allow for synthesis at a fast rate.
- at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 125, 150, 175, 200 nucleotides per hour, or more are synthesized.
- Nucleotides include adenine, guanine, thymine, cytosine, uridine building blocks, or analogs/modified versions thereof.
- libraries of polynucleotides are synthesized in parallel on substrate.
- a device comprising about or at least about 100; 1,000; 10,000; 30,000; 75,000; 100,000; 1,000,000; 2,000,000; 3,000,000; 4,000,000; or 5,000,000 resolved loci is able to support the synthesis of at least the same number of distinct polynucleotides, wherein polynucleotide encoding a distinct sequence is synthesized on a resolved locus.
- a library of polynucleotides is synthesized on a device with low error rates described herein in less than about three months, two months, one month, three weeks, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 days, 24 hours or less.
- nucleic acids assembled from a polynucleotide library synthesized with low error rate using the substrates and methods described herein are prepared in less than about three months, two months, one month, three weeks, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 days, 24 hours or less.
- methods described herein provide for generation of a library of nucleic acids comprising variant nucleic acids differing at a plurality of codon sites.
- a nucleic acid may have 1 site, 2 sites, 3 sites, 4 sites, 5 sites, 6 sites, 7 sites, 8 sites, 9 sites, 10 sites, 11 sites, 12 sites, 13 sites, 14 sites, 15 sites, 16 sites, 17 sites 18 sites, 19 sites, 20 sites, 30 sites, 40 sites, 50 sites, or more of variant codon sites.
- the one or more sites of variant codon sites may be adjacent. In some instances, the one or more sites of variant codon sites may not be adjacent and separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more codons.
- a nucleic acid may comprise multiple sites of variant codon sites, wherein all the variant codon sites are adjacent to one another, forming a stretch of variant codon sites. In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein none the variant codon sites are adjacent to one another. In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein some the variant codon sites are adjacent to one another, forming a stretch of variant codon sites, and some of the variant codon sites are not adjacent to one another.
- FIG. 2 illustrates an exemplary process workflow for synthesis of nucleic acids (e.g., genes) from shorter nucleic acids.
- the workflow is divided generally into phases: (1) de novo synthesis of a single stranded nucleic acid library, (2) joining nucleic acids to form larger fragments, (3) error correction, (4) quality control, and (5) shipment.
- an intended nucleic acid sequence or group of nucleic acid sequences is preselected. For example, a group of genes is preselected for generation.
- a predetermined library of nucleic acids is designed for de novo synthesis.
- Various suitable methods are known for generating high density polynucleotide arrays.
- a device surface layer is provided.
- chemistry of the surface is altered in order to improve the polynucleotide synthesis process. Areas of low surface energy are generated to repel liquid while areas of high surface energy are generated to attract liquids.
- the surface itself may be in the form of a planar surface or contain variations in shape, such as protrusions or microwells which increase surface area.
- high surface energy molecules selected serve a dual function of supporting DNA chemistry, as disclosed in International Patent Application Publication WO/2015/021080, which is herein incorporated by reference in its entirety.
- a deposition device such as a material deposition device 201, is designed to release reagents in a step wise fashion such that multiple polynucleotides extend, in parallel, one residue at a time to generate oligomers with a predetermined nucleic acid sequence 202.
- polynucleotides are cleaved from the surface at this stage. Cleavage includes gas cleavage, e.g., with ammonia or methylamine.
- the generated polynucleotide libraries are placed in a reaction chamber.
- the reaction chamber (also referred to as “nanoreactor”) is a silicon coated well, containing PCR reagents and lowered onto the polynucleotide library 203.
- a reagent is added to release the polynucleotides from the substrate.
- the polynucleotides are released subsequent to sealing of the nanoreactor 205. Once released, fragments of single stranded polynucleotides hybridize in order to span an entire long range sequence of DNA. Partial hybridization 205 is possible because each synthesized polynucleotide is designed to have a small portion overlapping with at least one other polynucleotide in the pool.
- a PCA reaction is commenced.
- the polynucleotides anneal to complementary fragments and gaps are filled in by a polymerase.
- Each cycle increases the length of various fragments randomly depending on which polynucleotides find each other. Complementarity amongst the fragments allows for forming a complete large span of double stranded DNA 206.
- the nanoreactor is separated from the device 207 and positioned for interaction with a device having primers for PCR 208. After sealing, the nanoreactor is subject to PCR 209 and the larger nucleic acids are amplified. After PCR 210, the nanochamber is opened 211, error correction reagents are added 212, the chamber is sealed 213 and an error correction reaction occurs to remove mismatched base pairs and/or strands with poor complementarity from the double stranded PCR amplification products 214. The nanoreactor is opened and separated 215. Error corrected product is next subject to additional processing steps, such as PCR and molecular bar coding, and then packaged 222 for shipment 223.
- additional processing steps such as PCR and molecular bar coding
- quality control measures are taken.
- quality control steps include for example interaction with a wafer having sequencing primers for amplification of the error corrected product 216, sealing the wafer to a chamber containing error corrected amplification product 217, and performing an additional round of amplification 218.
- the nanoreactor is opened 219 and the products are pooled 220 and sequenced 221. After an acceptable quality control determination is made, the packaged product 222 is approved for shipment 223.
- a nucleic acid generate by a workflow such as that in FIG. 2 is subject to mutagenesis using overlapping primers disclosed herein.
- a library of primers are generated by in situ preparation on a solid support and utilize single nucleotide extension process to extend multiple oligomers in parallel.
- a deposition device such as a material deposition device, is designed to release reagents in a step wise fashion such that multiple polynucleotides extend, in parallel, one residue at a time to generate oligomers with a predetermined nucleic acid sequence 202.
- any of the systems described herein may be operably linked to a computer and may be automated through a computer either locally or remotely.
- the methods and systems of the disclosure may further comprise software programs on computer systems and use thereof. Accordingly, computerized control for the synchronization of the dispense/vacuum/refill functions such as orchestrating and synchronizing the material deposition device movement, dispense action and vacuum actuation are within the bounds of the disclosure.
- the computer systems may be programmed to interface between the user specified base sequence and the position of a material deposition device to deliver the correct reagents to specified regions of the substrate.
- the computer system 300 illustrated in FIG. 3 may be understood as a logical apparatus that can read instructions from media 311 and/or a network port 305, which can optionally be connected to server 309 having fixed media 312.
- the system such as shown in FIG. 3 can include a CPU 301, disk drives 303, optional input devices such as keyboard 315 and/or mouse 316 and optional monitor 307.
- Data communication can be achieved through the indicated communication medium to a server at a local or a remote location.
- the communication medium can include any means of transmitting and/or receiving data.
- the communication medium can be a network connection, a wireless connection or an internet connection. Such a connection can provide for communication over the World Wide Web. It is envisioned that data relating to the present disclosure can be transmitted over such networks or connections for reception and/or review by a party 322 as illustrated in FIG. 3.
- FIG. 4 is a block diagram illustrating a first example architecture of a computer system 400 that can be used in connection with example instances of the present disclosure.
- the example computer system can include a processor 402 for processing instructions.
- processors include: Intel XeonTM processor, AMD OpteronTM processor, Samsung 32-bit RISC ARM 1176JZ(F)-S vl.OTM processor, ARM Cortex-A8 Samsung S5PC100TM processor, ARM Cortex-A8 Apple A4TM processor, Marvell PXA 930TM processor, or a fimctionally-equivalent processor. Multiple threads of execution can be used for parallel processing.
- multiple processors or processors with multiple cores can also be used, whether in a single computer system, in a cluster, or distributed across systems over a network comprising a plurality of computers, cell phones, and/or personal data assistant devices.
- a high speed cache 404 can be connected to, or incorporated in, the processor 402 to provide a high speed memory for instructions or data that have been recently, or are frequently, used by processor 402.
- the processor 402 is connected to a north bridge 406 by a processor bus 408.
- the north bridge 406 is connected to random access memory (RAM) 410 by a memory bus 412 and manages access to the RAM 410 by the processor 402.
- the north bridge 406 is also connected to a south bridge 414 by a chipset bus 416.
- the south bridge 414 is, in turn, connected to a peripheral bus 418.
- the peripheral bus can be, for example, PCI, PCI-X, PCI Express, or other peripheral bus.
- the north bridge and south bridge are often referred to as a processor chipset and manage data transfer between the processor, RAM, and peripheral components on the peripheral bus 418.
- the functionality of the north bridge can be incorporated into the processor instead of using a separate north bridge chip.
- system 400 can include an accelerator card 422 attached to the peripheral bus 418.
- the accelerator can include field programmable gate arrays (FPGAs) or other hardware for accelerating certain processing.
- FPGAs field programmable gate arrays
- an accelerator can be used for adaptive data restructuring or to evaluate algebraic expressions used in extended set processing.
- the system 400 includes an operating system for managing system resources; non-limiting examples of operating systems include: Linux, WindowsTM, MACOSTM, BlackBerry OSTM, iOSTM, and other functionally-equivalent operating systems, as well as application software running on top of the operating system for managing data storage and optimization in accordance with example instances of the present disclosure.
- system 400 also includes network interface cards (NICs) 420 and 421 connected to the peripheral bus for providing network interfaces to external storage, such as Network Attached Storage (NAS) and other computer systems that can be used for distributed parallel processing.
- NICs network interface cards
- FIG. 5 is a diagram showing a network 500 with a plurality of computer systems 502a, and 502b, a plurality of cell phones and personal data assistants 502c, and Network Attached Storage (NAS) 504a, and 504b.
- systems 502a, 502b, and 502c can manage data storage and optimize data access for data stored in Network Attached Storage (NAS) 504a and 504b.
- a mathematical model can be used for the data and be evaluated using distributed parallel processing across computer systems 502a, and 502b, and cell phone and personal data assistant systems 502c.
- Computer systems 502a, and 502b, and cell phone and personal data assistant systems 502c can also provide parallel processing for adaptive data restructuring of the data stored in Network Attached Storage (NAS) 504a and 504b.
- FIG. 5 illustrates an example only, and a wide variety of other computer architectures and systems can be used in conjunction with the various instances of the present disclosure.
- a blade server can be used to provide parallel processing.
- Processor blades can be connected through a back plane to provide parallel processing.
- Storage can also be connected to the back plane or as Network Attached Storage (NAS) through a separate network interface.
- processors can maintain separate memory spaces and transmit data through network interfaces, back plane or other connectors for parallel processing by other processors.
- some or all of the processors can use a shared virtual address memory space.
- FIG. 6 is a block diagram of a multiprocessor computer system using a shared virtual address memory space in accordance with an example instance.
- the system includes a plurality of processors 602a- f that can access a shared memory subsystem 604.
- the system incorporates a plurality of programmable hardware memory algorithm processors (MAPs) 606a-f in the memory subsystem 604.
- MAPs programmable hardware memory algorithm processors
- Each MAP 606a-f can comprise a memory 608a-f and one or more field programmable gate arrays (FPGAs) 610a-f.
- the MAP provides a configurable functional unit and particular algorithms or portions of algorithms can be provided to the FPGAs 610a-f for processing in close coordination with a respective processor.
- the MAPs can be used to evaluate algebraic expressions regarding the data model and to perform adaptive data restructuring in example instances.
- each MAP is globally accessible by all of the processors for these purposes.
- each MAP can use Direct Memory Access (DMA) to access an associated memory 608a-f, allowing it to execute tasks independently of, and asynchronously from the respective microprocessor 602a-f.
- DMA Direct Memory Access
- a MAP can feed results directly to another MAP for pipelining and parallel execution of algorithms.
- the above computer architectures and systems are examples only, and a wide variety of other computer, cell phone, and personal data assistant architectures and systems can be used in connection with example instances, including systems using any combination of general processors, co-processors, FPGAs and other programmable logic devices, system on chips (SOCs), application specific integrated circuits (ASICs), and other processing and logic elements.
- SOCs system on chips
- ASICs application specific integrated circuits
- all or part of the computer system can be implemented in software or hardware.
- Any variety of data storage media can be used in connection with example instances, including random access memory, hard drives, flash memory, tape drives, disk arrays, Network Attached Storage (NAS) and other local or distributed data storage devices and systems.
- NAS Network Attached Storage
- the computer system can be implemented using software modules executing on any of the above or other computer architectures and systems.
- the functions of the system can be implemented partially or completely in firmware, programmable logic devices such as field programmable gate arrays (FPGAs) as referenced in FIG. 4, system on chips (SOCs), application specific integrated circuits (ASICs), or other processing and logic elements.
- FPGAs field programmable gate arrays
- SOCs system on chips
- ASICs application specific integrated circuits
- the Set Processor and Optimizer can be implemented with hardware acceleration through the use of a hardware accelerator card, such as accelerator card 422 illustrated in FIG. 4.
- Example 1 Functionalization of a device surface
- a device was functionalized to support the attachment and synthesis of a library of polynucleotides.
- the device surface was first wet cleaned using a piranha solution comprising 90% H 2 SO 4 and 10% H 2 O 2 for 20 minutes.
- the device was rinsed in several beakers with DI water, held under a DI water gooseneck faucet for 5 min, and dried with N 2 .
- the device was subsequently soaked in NH 4 OH (1 : 100; 3 mL:300 mL) for 5 min, rinsed with DI water using a handgun, soaked in three successive beakers with DI water for 1 min each, and then rinsed again with DI water using the handgun.
- the device was then plasma cleaned by exposing the device surface to O 2 .
- a SAMCO PC-300 instrument was used to plasma etch O 2 at 250 watts for 1 min in downstream mode.
- the cleaned device surface was actively functionalized with a solution comprising N-(3- triethoxysilylpropyl)-4-hydroxybutyramide using a YES-1224P vapor deposition oven system with the following parameters: 0.5 to 1 torr, 60 min, 70 °C, 135 °C vaporizer.
- the device surface was resist coated using a Brewer Science 200X spin coater. SPRTM 3612 photoresist was spin coated on the device at 2500 rpm for 40 sec. The device was pre-baked for 30 min at 90 °C on a Brewer hot plate.
- the device was subjected to photolithography using a Karl Suss MA6 mask aligner instrument.
- the device was exposed for 2.2 sec and developed for 1 min in MSF 26A. Remaining developer was rinsed with the handgun and the device soaked in water for 5 min. The device was baked for 30 min at 100 °C in the oven, followed by visual inspection for lithography defects using a Nikon L200. A descum process was used to remove residual resist using the SAMCO PC-300 instrument to O2 plasma etch at 250 watts for 1 min.
- the device surface was passively functionalized with a 100 pL solution of perfluorooctyltrichlorosilane mixed with 10 pL light mineral oil.
- the device was placed in a chamber, pumped for 10 min, and then the valve was closed to the pump and left to stand for 10 min. The chamber was vented to air.
- the device was resist stripped by performing two soaks for 5 min in 500 mL NMP at 70 °C with ultrasonication at maximum power (9 on Crest system). The device was then soaked for 5 min in 500 mL isopropanol at room temperature with ultrasonication at maximum power.
- the device was dipped in 300 mL of 200 proof ethanol and blown dry with N2.
- the functionalized surface was activated to serve as a support for polynucleotide synthesis.
- Example 2 Synthesis of a 50-mer sequence on an oligonucleotide synthesis device
- a two dimensional oligonucleotide synthesis device was assembled into a flowcell, which was connected to a flowcell (Applied Biosystems (ABI394 DNA Synthesizer").
- the two-dimensional oligonucleotide synthesis device was uniformly functionalized with N-(3-TRIETHOXYSILYLPROPYL)-4- HYDROXYBUTYRAMIDE (Gelest) was used to synthesize an exemplary polynucleotide of 50 bp ("50- mer polynucleotide”) using polynucleotide synthesis methods described herein.
- the synthesis was done using standard DNA synthesis chemistry (coupling, capping, oxidation, and deblocking) according to the protocol in Table 2 and an ABI synthesizer.
- the flow restrictor was removed from the ABI 394 synthesizer to enable faster flow. Without flow restrictor, flow rates for amidites (0.1M in ACN), Activator, (0.25M Benzoylthiotetrazole ("BTT"; 30-3070- xx from GlenResearch) in ACN), and Ox (0.02M 12 in 20% pyridine, 10% water, and 70% THF) were roughly ⁇ 100uL/sec, for acetonitrile (“ACN”) and capping reagents (1:1 mix of CapA and CapB, wherein CapA is acetic anhydride in THF/Pyridine and CapB is 16% 1-methylimidizole in THF), roughly ⁇ 200uL/sec, and for Deblock (3% dichloroacetic acid in toluene), roughly ⁇ 300uL/sec (compared to ⁇ 50uL/sec for all reagents with flow restrictor).
- ACN acetonitrile
- Deblock 3% dichloroacetic acid in to
- Example 3 Synthesis of a 100-mer sequence on an oligonucleotide synthesis device [00226] The same process as described in Example 2 for the synthesis of the 50-mer sequence was used for the synthesis of a 100-mer polynucleotide ("100-mer polynucleotide"; 5'
- Thymidine-succinyl hexamide CED phosphoramidite (CLP-2244 from ChemGenes) on two different silicon chips, the first one uniformly functionalized with N-(3-TRIETHOXYSILYLPROPYL)-4- HYDROXYBUTYRAMIDE and the second one functionalized with 5/95 mix of 11- acetoxyundecyltriethoxysilane and n-decyltriethoxy silane, and the polynucleotides extracted from the surface were analyzed on a BioAnalyzer instrument.
- Table 4 summarizes error characteristics for the sequences obtained from the polynucleotides samples from spots 1-10.
- Example 4 Panning and screening for identification of antibodies for SARS-CoV-2 and ACE2
- This example describes identification of antibodies for SARS-CoV-2 and ACE2.
- FIG. 7 shows a schema of the panning strategy. Biotinylated antigen was bound to streptavidin coated magnetic beads at a density of 100 pmol antigen per mg of beads (Thermo Fisher #11206D). Phage libraries were blocked with 5% BSA in PBS. Following magnetic bead depletion for 1 hour at room temperature (RT), the beads were removed, and phage supernatant was transferred to 1 mg of antigen-bound beads in 1 ml PBS and incubated at RT with rotation for 1 hour.
- RT room temperature
- Non-binding clones were washed away by addition of 1 ml PBST, increasing the number of washes with each panning round. Trypsin was used to elute the phage bound to the antigen-bead complex. Phage were amplified in TGI E. coli for the next round of selection. This selection strategy was repeated for four rounds, with successively lower amounts of antigen per round. Following all four selection rounds, 400 clones from each of round 2, 3, and 4 were selected for phage expression and phage EFISA screening. Data from the panning is seen in Table 5. Table 5. Panning Data
- phage were expressed from each picked colony by K07 superinfection in 384 well microtiter plates. Phage containing supernatant was blocked by 1: 1 addition of 4% non-fat milk (NFM). Assay plates were prepared by passive immobilization of 0.4 pg antigen in 384-well Maxisorp plates (Thermo Fisher #464718) and then blocked with 4% NFM. Following 3x wash in PBST, blocked phage supernatant was incubated for 1 hour at RT.
- NFM non-fat milk
- FIGS. 9A-9D shows phage ELISA data from round 4 of SARS-CoV-2 SI (subunit 1) protein panning for antibody 1 (FIGS. 8A-8B) and antibody 2 (FIGS. 8C-8D).
- FIGS. 9A-9D shows phage ELISA data from round 4 of ACE2 protein panning for antibody 3 (FIGS. 9A- 9B) and antibody 4 (FIGS. 9C-9D).
- SARS-CoV-2 variants were tested for specificity using a phage ELISA as described above.
- the antigens used included Aero COVID SI (S1N-C82E8), COVID SI RBD Fc fusion (Antigen 1), and COVID SI RBM Fc fusion (Antigen 2).
- Data from the phage ELISA is seen in Table 6A.
- Table 6A shows screening ELISA mean, fold over background (column A), specificity ELISA, fold over background (column B), and specificity ELISA, percent binding relative to binding to Aero SI (column C).
- Tables 6B-6C show Carterra SPR kinetics for SARS-CoV-2 variant antibodies ranked by off-rate (Table 6B) and by KD (Table 6C).
- FIG. 10 shows that ACE2 binds to Sl-RBD-Fc and Sl-Fc variants.
- SARS-CoV-2 and ACE variant antibodies were tested for specificity and affinity.
- Recombinant SI Protein (Acres Biosystems Cat. No. S1N-S52H5) was passively immobilized on a 384 well ELISA plate and blocked with BSA.
- the SI Panel antibodies were diluted from 50 nM to 0.0076 nM and incubated with the blocked plate.
- Antibody binding was detected using Goat-anti -Human-HRP secondary and developed with HRP substrate (list here). The absorbance signal was plotted as % of maximal binding and fitted to determine the EC50 of each antibody using GraphPad Prism.
- FIGS 11A-11B Exemplary data for affinity of SARS-CoV-2 variant 2-6 is seen in FIGS 11A-11B.
- the binding of SARS-CoV-2 panel of antibodies was measured as seen in FIG. 12 and Tables 7A-7F below.
- SARS-CoV-2 Variants Frequency and ELISA Data Table 7C.
- SARS-CoV-2 SI Variants Frequency and ELISA Data Table 7C.
- Table 7E SARS-CoV-2 SI Variants Table 7F. Antibody Panel ELISA Binding Titrations (EC50)
- FIGS. 13A-13B and FIG. 14A Data for competition ELISA for a first set of SARS-CoV-2 SI RBD and ACE2 variant antibodies is seen in FIGS. 13A-13B and FIG. 14A.
- SARS-CoV-2 variant antibodies with high potency in order of potency included variant 2-2, Aero mAb (1.5333), variant 2-5, variant 1-12, and variant 2-9.
- ACE variant antibodies with high potency in order of potency included variant 4-52, variant 4-17, variant 4-39, Aero mAb (1.533), variant 4-54, and variant 3.5.
- Data for competition ELISA for a second set of ACE2 variant antibodies is seen in FIG. 14B.
- Variant antibodies with high potency in order of potency included variant 4- 101, variant 4-140, variant 4-121, variant 4-118, and Aero mAb (2.76 nM).
- FIGS. 14C-14D show the SARS-CoV-2 variant antibodies show potent neutralization.
- SARS-CoV-2 variant antibodies were assayed for Vero inhibition using FACS. Briefly, Vero cells stripped with Cell Stripper ( ⁇ 20 minutes with 90% viability after removal). Cells were plated at 0. lxlO 6 cells per well. Stock solution of the variant antibodies were at 200nM titrated 1:3. SARS-CoV-2 S protein RBD, SPD-C5259 were made up at 6ug/mL. Variant antibody titrations were mixed 1:1 with 6ug/mL S protein (50uL IgG: 50 uL S protein). 100 uL of the mixture were added to cells and then incubated on ice for 1 hour.
- the variant antibodies were also measured in binding against other coronaviruses. Data shows that the variant antibodies do not bind significantly to SI HCoV-229E (Sino), SI HCoV-HKUl (Sino), SI HCoV-NL63 (Sino), or SI HCoV-OC43 (Sino) (data not shown).
- VHH-Fc antibodies targeting S 1 were titrated 1 : 3 starting at 200 nM and mixed 1 : 1 with SARS- COV2-S1 RBD (mouse IgG2Fc tag).
- SARS- COV2-S1 RBD mouse IgG2Fc tag
- the RBD/VHH-Fc complex was added to Vero E6 cells expressing endogenous ACE2 receptor and incubated. Cells were subsequently washed and an anti-mouse secondary was used to measure binding of S 1 RBD to ACE2, thus assessing the inhibition of S 1.
- Over 60 clones demonstrated potent inhibition. Data is seen in FIGS. 18A-18C and Tables 11 and 12.
- FIGS. 19A-19B The data shows that the antibodies bind with nanomolar affinities.
- FIG. 19C shows percent neutralization for variants 1-12, 1-42 and 1-20.
- FIG. 19D shows percent neutralization for variants 1-12, 1-42 and 1-20 using live virus.
- VHH-Fc antibodies targeting S 1 were titrated 1 : 3 starting at 200 nM and mixed 1 : 1 with SARS- COV2-S1 RBD (mouse IgG2Fc tag).
- SARS- COV2-S1 RBD mouse IgG2Fc tag
- the RBD/VHH-Fc complex was added to Vero E6 cells expressing endogenous ACE2 receptor and incubated. Cells were subsequently washed and an anti-mouse secondary was used to measure binding of S 1 RBD to ACE2, thus assessing the inhibition of S 1.
- Over 60 clones demonstrated potent inhibition. The data is seen in FIGS. 20A-20B and Table 13.
- FIG. 20B shows that variant 6-2 showed higher neutralization versus IgG in live virus.
- Variants 6- 63, 6-3, and 5-1 showed comparable neutralization versus 2165 mAb derived from a COVID-19 subject.
- FIGS. 20C-20E and Table 14 show data from VHH single domain antibodies in VSV-pseudotype SARS-CoV-2 neutralization assays.
- Variants 5-1, 6-3, and 6-63 showed improved neutralization in pseudovirus testing including in live virus FRNT (FIG. 20E).
- Variants 6-3, 6-60, 6-63, and 6-76 showed potent neutralization in live virus PRNT as seen in Table 15 and FIG. 20F.
- Data as seen in Table 16 and FIGS. 20G-20H show that variants 6-3, 6-63, and 1-20 exhibited potent neutralization in live virus PRNT. Table 14.
- variants 5- 20, 6-60, 6-63, and 6-3 showed potent neutralization in live virus PRNT as seen in FIG. 201.
- This Example assesses the variant coronavirus immunoglobulins in a Syrian hamster model
- FIG. 3421E shows data from the variant antibodies grouped by dose.
- FIG. 21F shows graphs of percent weight change for antibodies 6-3, 6-63, and 1-20.
- Lung pathology inflammation and edema scores from three animals were added per group and plotted (Fig. 211). These were the same lungs used to score ISH.
- the convalescent sera positive control median score was 2 and the negative control was 4.
- the only groups with a median score lower than the negative control group were 1 and 5 mg/kg 6-63, 10 and 5 mg/kg 6-3, and 5 mg/kg 1-20.
- the highest median pathology scores were the 1 and 10 mg/kg 1-20 groups.
- the lowest median pathology score was the 5 mg/kg 6-63 group.
- Example 9 VSV- pseudotype neutralization analysis of antibodies for SARS-CoV-2 B.135 (South African strain)
- Antibodies described herein were tested in a VSV-pseudotype neutralization assay for SARS-CoV-2 B.135 (South African strain).
- FIGS. 22A-22B Data is seen in FIGS. 22A-22B.
- FIG. 22A illustrates positive control pAb has an NT50 of 1: 14, 993 dilution as expected.
- FIG. 22B illustrates antibodies 6-63 and 6-3 neutralize VSV-SARS B.135 strain with IC50s of -3.07 ug/mL and 0.143 ug/mL, respectively.
- Antibody 1-12 failed to neutralize VSV-SARS B.135 strain.
- Example 10 VSV-pseudotype neutralization analysis of antibodies for SARS-CoV-2 D614G variant
- Antibodies described herein were tested in a VSV-pseudotype neutralization assay for SARS-CoV-2 SARS CoV-2 S D614G variant.
- FIGS. 23A-23C Data is seen in FIGS. 23A-23C.
- FIG. 23A shows the positive control.
- Example 11 Antibody cocktails for treating SARS-CoV-2 in Syrian hamsters
- This Example demonstrates pre- and post-exposure efficacy of antibody cocktails in Syrian hamsters.
- hamsters were transiently immunosuppressed using cyclophosphamide.
- nAb nanobody
- MAb monoclonal antibody
- the cocktail consisted of lOmg/Kg of VHH nanobody 6-63 and lOmg/Kg of monoclonal antibody 1-20. An equal number of male and female animals were used in each group.
- MAb/nAb cocktail or c7Dl 1 was administered via the intraperitoneal (IP) route.
- IP intraperitoneal
- Group I was also the control for any adverse effects of cyclophosphamide treatment on the hamsters.
- Clinical scores and individual animal weights were recorded daily. Pharyngeal swabs and other key events are listed in Table 18B.
- Animals in Groups A-I were euthanized on day 14 and lungs were collected for virology and pathology.
- Group J animals were used for a serial pathology component of this study. Two animals from Group J (2 male and 2 female) were euthanized starting on Day 1 and then each day up to and including Day 6.
- Cyclophosphamide treatment in uninfected animals does not result in weight loss.
- Control animals CYP Controls, Group I
- Post-exposure treatment of CYP hamster model of COVID19 produces variable weight loss effects/patterns.
- a onetime treatment of a cocktail containing 1-20 and 6-63 at final dose of 20mg/Kg was administered on Days 1 (B), 2 (C), 3 (D), 4 (E), 5 (F), and 6 (G).
- the percent weight change relative to Day 0 are shown in FIG. 24A.
- Arrows and dotted vertical lines indicate the day of treatment specific for the treatment regimen being compared.
- the same data is shown collectively in FIG. 24B. Note that there were two animals in Group B (Day 1) that dropped weight atypically during the experiment and one animal succumbed on Day 12.
- Treatment with the cocktail two days after exposure clearly protected. There was significant differences in AOC between Group C and Group H; and no significant difference in the AOC between Group C and Group I. Treatment after three days (Day 3 Group D) did not result in a significant difference in AOC between Group D and H. However, treatment on day 4 or 5 after exposure (Groups E and F, respectively) did significant reduce the AOC relative to Group H. Treatment on day 6 (Group G) was similar to treatment on day 3 where no significant difference in AOR between Group G and H. Although there was no significance in the AOC for the Day 6 treatment group, the last three timepoints weight loss was significantly less than the negative control group. Interestingly, groups administered antibody on Days 3, 4, 5, or 6 started to gain weight starting on Day 9 whereas the negative control antibody treated animals did not. This suggests that there was a benefit of all cocktail treatment even at as late as 6 days post-exposure.
- Example 12 Immunity conferred by SARS-CoV-2 and ACE2 antibodies
- Antibodies described in Examples 4-6 are used to confer immunity in a subject.
- a subject is passively immunized with a SARS-CoV-2 or ACE2 antibody.
- the subject is then exposed to SARS-CoV-2 after immunization with the SARS-CoV-2 or ACE2 antibody. Exposure can be within a few days or within a few months.
- the subject can also receive the SARS-CoV-2 or ACE2 antibody immediately following exposure with SARS-CoV-2. Although the subject is exposed to SARS-CoV-2, the subject has developed an immunity against SARS-CoV-2 and infection is prevented.
- Tables 19-25 show exemplary sequences for CDRH1-H3 and CDRL1-L3 as well as variant heavy chains and variant light chains for the SARS-CoV-2 and ACE2 variants.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021263755A AU2021263755A1 (en) | 2020-04-27 | 2021-04-27 | Variant nucleic acid libraries for Coronavirus |
JP2022565726A JP2023523336A (en) | 2020-04-27 | 2021-04-27 | Mutant nucleic acid library for coronavirus |
CA3177030A CA3177030A1 (en) | 2020-04-27 | 2021-04-27 | Variant nucleic acid libraries for coronavirus |
EP21796107.7A EP4142739A2 (en) | 2020-04-27 | 2021-04-27 | Variant nucleic acid libraries for coronavirus |
CN202180045891.0A CN116113420A (en) | 2020-04-27 | 2021-04-27 | Variant nucleic acid libraries for coronaviruses |
BR112022021789A BR112022021789A2 (en) | 2020-04-27 | 2021-04-27 | CORONAVIRUS VARIANT NUCLEIC ACID LIBRARIES |
KR1020227041294A KR20230016184A (en) | 2020-04-27 | 2021-04-27 | Variant nucleic acid library for coronavirus |
IL297701A IL297701A (en) | 2020-04-27 | 2021-04-27 | Variant nucleic acid libraries for coronavirus |
MX2022013513A MX2022013513A (en) | 2020-04-27 | 2021-04-27 | Variant nucleic acid libraries for coronavirus. |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063016254P | 2020-04-27 | 2020-04-27 | |
US63/016,254 | 2020-04-27 | ||
US202063034896P | 2020-06-04 | 2020-06-04 | |
US63/034,896 | 2020-06-04 | ||
US202063069665P | 2020-08-24 | 2020-08-24 | |
US63/069,665 | 2020-08-24 | ||
US202063073362P | 2020-09-01 | 2020-09-01 | |
US63/073,362 | 2020-09-01 | ||
US202063104465P | 2020-10-22 | 2020-10-22 | |
US63/104,465 | 2020-10-22 | ||
US202063115568P | 2020-11-18 | 2020-11-18 | |
US63/115,568 | 2020-11-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021222315A2 true WO2021222315A2 (en) | 2021-11-04 |
WO2021222315A3 WO2021222315A3 (en) | 2021-12-09 |
Family
ID=78374237
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/029486 WO2021222316A2 (en) | 2020-04-27 | 2021-04-27 | Variant nucleic acid libraries for coronavirus |
PCT/US2021/029485 WO2021222315A2 (en) | 2020-04-27 | 2021-04-27 | Variant nucleic acid libraries for coronavirus |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/029486 WO2021222316A2 (en) | 2020-04-27 | 2021-04-27 | Variant nucleic acid libraries for coronavirus |
Country Status (11)
Country | Link |
---|---|
US (2) | US20210395344A1 (en) |
EP (2) | EP4142739A2 (en) |
JP (2) | JP2023523336A (en) |
KR (2) | KR20230016184A (en) |
CN (2) | CN116113420A (en) |
AU (2) | AU2021263756A1 (en) |
BR (2) | BR112022021780A2 (en) |
CA (2) | CA3177029A1 (en) |
IL (2) | IL297701A (en) |
MX (2) | MX2022013499A (en) |
WO (2) | WO2021222316A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3722442B1 (en) | 2013-08-05 | 2023-04-05 | Twist Bioscience Corporation | De novo synthesized gene libraries |
WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
WO2017049231A1 (en) | 2015-09-18 | 2017-03-23 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
KR20180058772A (en) | 2015-09-22 | 2018-06-01 | 트위스트 바이오사이언스 코포레이션 | Flexible substrate for nucleic acid synthesis |
CN110248724B (en) | 2016-09-21 | 2022-11-18 | 特韦斯特生物科学公司 | Nucleic acid based data storage |
SG11201907713WA (en) | 2017-02-22 | 2019-09-27 | Twist Bioscience Corp | Nucleic acid based data storage |
KR102628876B1 (en) | 2017-06-12 | 2024-01-23 | 트위스트 바이오사이언스 코포레이션 | Methods for seamless nucleic acid assembly |
WO2019051501A1 (en) | 2017-09-11 | 2019-03-14 | Twist Bioscience Corporation | Gpcr binding proteins and synthesis thereof |
KR102637566B1 (en) | 2017-10-20 | 2024-02-16 | 트위스트 바이오사이언스 코포레이션 | Heated nanowells for polynucleotide synthesis |
AU2019270243A1 (en) | 2018-05-18 | 2021-01-07 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
EP3930753A4 (en) | 2019-02-26 | 2023-03-29 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
WO2020176680A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
WO2020257612A1 (en) | 2019-06-21 | 2020-12-24 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
MX2022013499A (en) * | 2020-04-27 | 2023-01-16 | Twist Bioscience Corp | Variant nucleic acid libraries for coronavirus. |
US20220348659A1 (en) * | 2021-03-24 | 2022-11-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for cd3 |
WO2023091614A2 (en) * | 2021-11-18 | 2023-05-25 | Twist Bioscience Corporation | Dickkopf-1 variant antibodies and methods of use |
WO2023102034A2 (en) * | 2021-12-01 | 2023-06-08 | Twist Bioscience Corporation | Neuropilin-1 variant antibodies and methods of use |
US20230257448A1 (en) * | 2022-01-03 | 2023-08-17 | Twist Bioscience Corporation | Bispecific sars-cov-2 antibodies and methods of use |
WO2023235827A2 (en) * | 2022-06-03 | 2023-12-07 | The Rockefeller University | Coronavirus-inhibiting antibodies |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012360A2 (en) * | 2003-07-22 | 2005-02-10 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
US7566772B2 (en) * | 2005-01-26 | 2009-07-28 | Amgen Fremont Inc. | Antibodies against interleukin-1β |
US9403904B2 (en) * | 2008-11-07 | 2016-08-02 | Fabrus, Inc. | Anti-DLL4 antibodies and uses thereof |
ES2711554T3 (en) * | 2012-05-22 | 2019-05-06 | Bristol Myers Squibb Co | Bispecific antibodies against IL-17A / F IL-23 and its uses |
WO2018128939A1 (en) * | 2017-01-05 | 2018-07-12 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
KR20200053437A (en) * | 2017-05-08 | 2020-05-18 | 아디맵 엘엘씨 | Anti-CD3-binding domains and antibodies comprising them, and methods of generating and using them |
MX2022013499A (en) * | 2020-04-27 | 2023-01-16 | Twist Bioscience Corp | Variant nucleic acid libraries for coronavirus. |
US20220206001A1 (en) * | 2020-10-22 | 2022-06-30 | Twist Bioscience Corporation | Methods and systems for detecting coronavirus |
US20230002478A1 (en) * | 2021-06-22 | 2023-01-05 | Twist Bioscience Corporation | Methods and compositions relating to covid antibody epitopes |
-
2021
- 2021-04-27 MX MX2022013499A patent/MX2022013499A/en unknown
- 2021-04-27 KR KR1020227041294A patent/KR20230016184A/en unknown
- 2021-04-27 AU AU2021263756A patent/AU2021263756A1/en active Pending
- 2021-04-27 AU AU2021263755A patent/AU2021263755A1/en active Pending
- 2021-04-27 IL IL297701A patent/IL297701A/en unknown
- 2021-04-27 JP JP2022565726A patent/JP2023523336A/en active Pending
- 2021-04-27 EP EP21796107.7A patent/EP4142739A2/en not_active Withdrawn
- 2021-04-27 JP JP2022565725A patent/JP2023523335A/en active Pending
- 2021-04-27 WO PCT/US2021/029486 patent/WO2021222316A2/en active Application Filing
- 2021-04-27 IL IL297700A patent/IL297700A/en unknown
- 2021-04-27 US US17/242,179 patent/US20210395344A1/en not_active Abandoned
- 2021-04-27 CA CA3177029A patent/CA3177029A1/en active Pending
- 2021-04-27 BR BR112022021780A patent/BR112022021780A2/en unknown
- 2021-04-27 CN CN202180045891.0A patent/CN116113420A/en active Pending
- 2021-04-27 EP EP21797661.2A patent/EP4142784A2/en active Pending
- 2021-04-27 BR BR112022021789A patent/BR112022021789A2/en unknown
- 2021-04-27 KR KR1020227041289A patent/KR20230017781A/en unknown
- 2021-04-27 WO PCT/US2021/029485 patent/WO2021222315A2/en active Application Filing
- 2021-04-27 CA CA3177030A patent/CA3177030A1/en active Pending
- 2021-04-27 US US17/242,170 patent/US20210355194A1/en active Pending
- 2021-04-27 CN CN202180045924.1A patent/CN116209463A/en active Pending
- 2021-04-27 MX MX2022013513A patent/MX2022013513A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3177029A1 (en) | 2021-11-04 |
MX2022013513A (en) | 2023-01-16 |
IL297701A (en) | 2022-12-01 |
CA3177030A1 (en) | 2021-11-04 |
WO2021222316A3 (en) | 2021-12-09 |
US20210395344A1 (en) | 2021-12-23 |
BR112022021789A2 (en) | 2023-03-07 |
KR20230017781A (en) | 2023-02-06 |
MX2022013499A (en) | 2023-01-16 |
IL297700A (en) | 2022-12-01 |
AU2021263756A1 (en) | 2022-12-15 |
EP4142739A2 (en) | 2023-03-08 |
WO2021222316A2 (en) | 2021-11-04 |
BR112022021780A2 (en) | 2023-03-07 |
CN116209463A (en) | 2023-06-02 |
KR20230016184A (en) | 2023-02-01 |
US20210355194A1 (en) | 2021-11-18 |
JP2023523335A (en) | 2023-06-02 |
EP4142784A2 (en) | 2023-03-08 |
JP2023523336A (en) | 2023-06-02 |
CN116113420A (en) | 2023-05-12 |
WO2021222315A3 (en) | 2021-12-09 |
AU2021263755A1 (en) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4142739A2 (en) | Variant nucleic acid libraries for coronavirus | |
US20210102195A1 (en) | Variant nucleic acid libraries for single domain antibodies | |
US20210179724A1 (en) | Variant nucleic acid libraries for adenosine receptors | |
US20220135690A1 (en) | Methods and compositions relating to chemokine receptor variants | |
WO2021061829A1 (en) | Variant nucleic acid libraries for crth2 | |
US20220307010A1 (en) | Variant nucleic acid libraries for tigit | |
US20220356468A1 (en) | Variant nucleic acid libraries for ion channels | |
US20220348659A1 (en) | Variant nucleic acid libraries for cd3 | |
US20220411784A1 (en) | Variant nucleic acid libraries for glycans | |
US20230192819A1 (en) | Single domain antibodies for sars-cov-2 | |
US20230192818A1 (en) | Sars-cov-2 antibodies and related compositions and methods of use | |
WO2023076420A2 (en) | Multispecific sars-cov-2 antibodies and methods of use | |
WO2023076419A2 (en) | Sars-cov-2 antibodies and methods of use | |
WO2024064310A2 (en) | Variant nucleic acid libraries for tigit | |
WO2023091614A2 (en) | Dickkopf-1 variant antibodies and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2022565726 Country of ref document: JP Kind code of ref document: A Ref document number: 3177030 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 297701 Country of ref document: IL |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022021789 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021796107 Country of ref document: EP Effective date: 20221128 |
|
ENP | Entry into the national phase |
Ref document number: 2021263755 Country of ref document: AU Date of ref document: 20210427 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21796107 Country of ref document: EP Kind code of ref document: A2 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022021789 Country of ref document: BR Free format text: APRESENTE O RELATORIO DESCRITIVO. |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522441100 Country of ref document: SA |
|
ENP | Entry into the national phase |
Ref document number: 112022021789 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221026 |